Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >


arjan1972
Posted on: Jan 15 2020, 07:48 AM


Group: Member
Posts: 135

I guess it just made its way to the market 😉
  Forum: By Share Code

arjan1972
Posted on: Nov 20 2019, 09:14 PM


Group: Member
Posts: 135

I personally was more then surprised that Clinuvel highlighted the 'Endgame' (DNA Repair / Skin Cancer preventive) at the AGM.
We all know how careful PW was and probably still is in communicating possible indications & therapies. And this is without doubt one of the most significant possible treatments. IMO he/they must be quite sure that it will work.
It might take a while before experts, media and analyst will dive into this but when this story goes around, it will be big. I am also quite curious what this could mean for the Clinuvel valuation.




  Forum: By Share Code

arjan1972
Posted on: Sep 12 2019, 10:37 AM


Group: Member
Posts: 135

I am long since 2005 and see no reason to sell after a positive announcement. There is more to come and I want to be there when it happens.

GLTA
  Forum: By Share Code

arjan1972
Posted on: May 9 2019, 03:58 PM


Group: Member
Posts: 135

We're all going to die, all of us, what a circus! That alone should make us love each other but it doesn't. We are terrorized and flattened by trivialities, we are eaten up by nothing.
(Charles Bukowski)

Peace
  Forum: By Share Code

arjan1972
Posted on: May 5 2019, 06:24 PM


Group: Member
Posts: 135

Unpleasant fall back? The stock doubled in approximately 2.5 months just to fall back 50% in one day (after rejection). Easy come, easy go.
Considering the chance that they will succeed next time it might be a unique opportunity to buy in.
  Forum: By Share Code

arjan1972
Posted on: Mar 20 2019, 05:26 PM


Group: Member
Posts: 135

Copy that, all good & nothing changed.
  Forum: By Share Code

arjan1972
Posted on: Sep 17 2017, 07:20 PM


Group: Member
Posts: 135

one of the major weekly newsmagazines in Germany 'Stern' writes about EPP and the struggle of patients to get the medicine. It describes the bureaucracy and the frustration of patients and doctors. Positive point, there is no doubt about the effectiveness. They also mentioned that side effects (over a measured period of 20 years) are minimal. Nothing new for us but ..

http://www.stern.de/gesundheit/haut/hauter...ht-7618032.html
  Forum: By Share Code

arjan1972
Posted on: Oct 28 2016, 03:43 PM


Group: Member
Posts: 135

Exciting times

I can smell the cigar... lmaosmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Oct 10 2016, 06:20 PM


Group: Member
Posts: 135

The conversion rate is fine for me.

Think big
  Forum: By Share Code

arjan1972
Posted on: Oct 10 2016, 03:19 PM


Group: Member
Posts: 135

Gentlemen

There is a cigar to win?

8,52€


Davidoff Escurio
  Forum: By Share Code

arjan1972
Posted on: Feb 13 2016, 04:51 AM


Group: Member
Posts: 135

Interesting (long) read about the European regulations on pricing

http://www.vfa.de/download/herstellerabgab...telmaerkten.pdf (In English starting at page 20)

Here a smal excerpt

24. For six regulations on the supply side, which have a direct and effective impact on the formation of the sales price of the manufacturer (price fixing and negotiation, discounts and reimbursements as well as price intervention and IRP), three regulation concepts with two versions each can be identified for the 21 most important EU countries. These concepts increase from top to bottom in terms of the regulatory density and intensity:
Free pricing
 without additional regulation on the supply side (Denmark, Sweden) or
 with additional regulation on the supply side, such as discounts, reimbursements and
price intervention (Germany, Great Britain). Price negotiation
 with the exception of IRP without additional regulation on the supply side (Ireland, Austria) or
 with additional regulations on the supply side, such as discounts, reimbursements, price intervention and IRP (France, Italy, Hungary).
Price setting
 with prior price negotiations and additional regulation on the supply side, such as reimbursements and IRP (Poland, Estonia, Latvia) or
 without prior price negotiations and with additional regulation on the supply side, such as reimbursements, price intervention and IRP (Netherlands, Belgium, Finland, Spain, Greece, Portugal, Slovenia, Slovakia, Czech Republic).


A long read but an interesting one. Have fun : )
  Forum: By Share Code

arjan1972
Posted on: Feb 10 2014, 12:26 AM


Group: Member
Posts: 135

FDA and EMA are not going to help clinuvel. They are working with rules and protocols Nobody really understands not to mention the close relationship with big pharma. How else is it explainable that companies like GSK get their licensed influenza vaccine on the market in no time because of the possible pandemic risks. (Which I think are BS stories) These authorities have the power to postpone decisions until eternity if they want so. Life is to short for that nonsense.
If I was suffering from EPP I would buy my MT1 or MT2 from the black market as long as necessary - al those years wasting and waiting for the gentleman of the EMA/FDA to confirm what is quite clear already. It's working and it's safe. What motive do they have to keep it from the market that long? It's frustrating
  Forum: By Share Code

arjan1972
Posted on: Feb 10 2014, 12:00 AM


Group: Member
Posts: 135

Just watched the movie 'dallas buyers club' and came to the conclusion that nothing has really changed. : (

  Forum: By Share Code

arjan1972
Posted on: Aug 2 2013, 06:46 PM


Group: Member
Posts: 135

Of course the situation is frustrating but it's reality and it is not that unexpected.What can happen will happen- that's the lesson I learned with biotech and pharma stock. But regarding Clinuvel I don't see reasons to panic and sell my cuv stock. This was and is a high risk company, a one trick pony with limited cash. They are not very good in communicating to their investors and never kept a timeline. It is what it is. The only chance to get over this status is through approval from EMA and/or FDA. Nevertheless I think clinuvel did come a long way - the Finnish is in sight.. But this is a ultra long marathon, they are not sprinting the final meters..
  Forum: By Share Code

arjan1972
Posted on: Apr 7 2013, 10:22 PM


Group: Member
Posts: 135

Just returned from Vegas and still feeling like sitting in the center of Caesars palace behind the biggest slot machine. This time with the name clinuvel.. Unbelievable what a bad verbalized press release does with your investors.. Sorry, what I meant to say was, unbelievable to think that PW doesn't know what a bad verbalized press release does with his investors. We don't even know if it was EMA or Clinuvel who needs more time.. No real reason, no nothing. Absolute chaos. Why did PW allow this kind of communication? The only thing this press release accomplished is that I now know that I know nothing anymore. With this kind of information it's impossible to say something about the chances that clinuvel has to get scenesse approved anytime
I can't imagine that - new investors - are ready to invest in a company with more risk than a slot machine..
this in combination with a bad financial situation will get us all into a big climax.
I guess the professional players just took over. Good luck
  Forum: By Share Code

arjan1972
Posted on: Mar 6 2013, 04:03 PM


Group: Member
Posts: 135

Good Times - the approval has to come soon now
In the main time, here another interesting TED Talk. A dermatologist explaining that sunlight isn't that bad after all..
http://www.ted.com/talks/richard_weller_co...your_heart.html
Enjoy & good luck for all of us

  Forum: By Share Code

arjan1972
Posted on: Jan 1 2013, 08:26 PM


Group: Member
Posts: 135

http://www.dailymotion.com/video/xn8cg8_te...ch#.UOK5C5G9KK0
Here a nice explanation about the algorithm behind it, also a must see for all stock traders
Happy new year!
  Forum: By Share Code

arjan1972
Posted on: Nov 13 2012, 12:51 AM


Group: Member
Posts: 135

Coincidence? possible but I think not..
Mr. Homms business is al about timing, and this is truly the best timing to set some extra rumours about this small australian biotech company and create some real momentum. And, honestly, why should he mention it in his book?

We will see.
  Forum: By Share Code

arjan1972
Posted on: Nov 12 2012, 04:57 PM


Group: Member
Posts: 135

@ 2hotty
http://www.skindisorders.com.au/skin-disor...clinuvel-stake/
  Forum: By Share Code

arjan1972
Posted on: Nov 12 2012, 07:46 AM


Group: Member
Posts: 135

For all the 'Old-Timers' in this Forum.. Florian Homm gave an interview. Mr.Homm is still on the run..
http://www.faz.net/aktuell/wirtschaft/mens...s-11953077.html
Mr Homm did the interview to promote his book. In this book he describes a young Australian Biotech company which - he saved - and now is going to boom..
(It's in German but I guess that google translate can help.)

  Forum: By Share Code

arjan1972
Posted on: Oct 7 2011, 12:59 AM


Group: Member
Posts: 135

Steve Jobs also advised to 'stay hungry, stay foolish'
i guess cuv is in my case the foolish part..
  Forum: By Share Code

arjan1972
Posted on: Oct 1 2011, 03:55 AM


Group: Member
Posts: 135

cuv dropped another 9%(!) in Frankfurt. Down to 1 Euro caused by somebody who sold 6000 shares well after the markets closed.. (18:30 - 18:45 CET) what's that all about?

Not a good start in the WE. Of course the whole market went down today but then again 9%? that's a lot.. why? There is no real news from Clinuvel only a new blog from PW with nothing new in it.. or did i miss something?
Attached image(s)
Attached Image

 
  Forum: By Share Code

arjan1972
Posted on: Jul 11 2011, 05:10 AM


Group: Member
Posts: 135

Bimatoprost (sold in the U.S., Canada and Europe under the trade name Lumigan) seems to work as a treatment for vitiligo. It is approved by the FDA since 2008 so off label prescribing is possible.. and it seems to be much cheaper then scenesse ever will be.

Bad news for Clinuvel, good news for all Vitiligo patients
  Forum: By Share Code

arjan1972
Posted on: Jun 23 2011, 01:26 AM


Group: Member
Posts: 135

a long but very interesting read..

Biotech and the Unintended Consequences of Moore's Law

By Pat Cox, Editor
Breakthrough Technology Alert
Transistor density doubles roughly every two years, as Moore's law attests. Information technology
therefore advances exponentially. You don't even have to know what a transistor is to feel the impact of
this extraordinary phenomenon. Mobile computing is an example. From new phone features and tablets
to the bandwidth that connects them to the cloud, the innovation is dizzying.
2
Elsewhere, however, even greater advances are being enabled by exponential improvements in
processor power. I'm referring to biotechnology but not just high-tech medical gadgets, though they do
exist.
Echo Therapeutics is a great example, with a device on track for approval that will replace hypodermic
needles in many medical applications. Smaller than an electric toothbrush, the transdermal skin
permeation device utilizes integrated circuits and sensors to painlessly remove the top dead layer of
skin using microdermabrasion. With direct access to the epidermis, drugs can be infused with
absolutely no discomfort. Analytes such as glucose, lactic acid or drug levels can be measured and
transmitted to anybody with a cell phone or mobile device.
Echo Therapeutics' first customers will be hospital staff who will use the technology to quickly
anesthetize needle sites in preparation for transfusion or blood extraction. Cosmetic surgeons, however,
want this technology to quickly prepare patients for dermal filler and Botox procedures.
Combined with a dollar-sized sensing wafer that attaches to the skin, the technology can be used to
provide continual needle-free glucose and other analyte monitoring. Real-time readings can be sent
wirelessly to a medical display or phones belonging to doctors, nurses, parents or the users themselves.
While this continual needle-free technology will make outpatients' lives more pleasant and healthier,
the biggest impact is likely to be on both the cost and quality of hospital care.
Continual glucose monitoring would cut hospital costs by freeing several hours of the average nurse's
day from tedious manual blood sugar testing. More importantly, studies indicate that close observation
and control of glucose levels in hospitals improves every indicator, from costs, length of stay and
mortality, by about a third. Given the serious need to manage health care expenditures, this cost-saving
manifestation of Moore's law will have a dramatic beneficial impact on health care.
Moore's law is yielding far greater benefits in regenerative or stem cell medicine, the only technology
capable of directly addressing age-related degenerative disease. Breathtaking advances are taking place
daily in stem cell science thanks to advances in bioinformatics, the application of statistics and
mathematics to cellular biology via information processing.
Ironically, however, almost no one knows about this accelerating revolution. Many, in fact, deny it. For
that reason, I'm providing an update of the two stem cell companies I consider most important.
Outside of the biotech community, advances are consistently underestimated. Many factors contribute
to this lack of public understanding. To begin with, the details of biotech are simply intimidating to
most people. The basics of computing, by contrast, are actually quite simple. With a little effort, nearly
anybody can grasp those basics. Since the first integrated circuits were created in the 1950s, most
progress in computing has come from engineering smaller, faster components.
The complexity of the biological sciences, on the other hand, dwarfs computer science. This isn't
surprising. There are more switches in one human brain than all the computers in the world. The cells
in only one person's body contain more information, encoded in DNA, than all the information
accessed by Google – by many orders of magnitude. No single scientist today is capable of staying
current in the many esoteric areas of the biological sciences.
This complexity, however, contributes to a huge gap between the public's understanding of biotech and
3
the actual state of the science. There are other factors at work as well. Foremost are two enormous
labyrinthine agencies, the FDA and the SEC. Both of these regulatory bodies monitor and restrict what
biotech firms can tell the public. These limitations may be benign in intent but they impede the flow of
information.
Typically, the public hears about new biotechnologies only when they achieve regulatory approval and
come to market. Winning approval for a drug or device, however, is an enormously expensive and
drawn out process.
As a result, most biotech products coming to market today are five to ten years old. Some are much
older. If personal computing had to jump the same kind of preclinical and clinical hurdles as biotech
companies, we would still be using computers the size of suitcases with cathode ray tube monitors. The
latest phones would do little more than provide intermittent voice communication.
Information about new biotechnologies is further limited by researchers themselves. Those working on
emerging technologies may not want to attract competitors by trumpeting accomplishments.
Even when private sector and academic researchers want to get word out about a new technology, they
often cannot find journalists capable of understanding and telling their stories. Financial distress in the
publishing business has exacerbated this problem.
The bottom line is that widely-held opinions about biotech are often very wrong. These
misconceptions, in turn, often have serious consequences. I'll give you several examples involving the
two stem cell companies I referred to before, BioTime, Inc. and International Stem Cell Corporation as
well as a nanomedicine firm, NanoViricides, Inc.
The Case of the Missing Parthenogenetic Stem Cells
When discussing stem cells, most commentators talk about three stem cell types. The first is adult stem
cells, which have proven disappointing to researchers. Their potential to become different cell types is
limited and they are as old as the donor. The other two stem cell types commonly discussed are both
pluripotent stem cells, meaning they do not age and are capable of becoming any cell type. These are
embryonic stem cells (heSCs) and induced pluripotent stem cells (iPSCs). There is, in fact, an
extremely important third form of pluripotent stem cell.
These are human parthenogenetic stem cells (hpSCs). International Stem Cell Corporation, usually
referred to by its acronym ISCO, pretty much has this stem cell type to themselves because they
developed the technique for creating parthenogenetic stem cell lines and own the intellectual property
governing those processes. This is a very good position to be in because hpSCs have distinct
advantages in many medical procedures.
Parthenogenetic stem cells are derived from unfertilized human oocytes (eggs). This negates the
concerns of those who believe that the use of embryonic stem cells is unethical. There is no shortage of
oocytes because they are collected and discarded routinely in normal fertilization procedures.
Among the leading scientists who have studied and validated the therapeutic potential of hpSCs is
George Daley, MD, PhD. Daley is Professor of Biological Chemistry and Molecular Pharmacology at
Harvard and Director of the Stem Cell Transplantation Program at Children's Hospital Boston.
4
His journal article, “Histocompatible Embryonic Stem Cells by Parthenogenesis,” describes another
reason researchers are interested in hpSCs. Histocompatability refers to ability to avoid immune
rejection. Immune rejection is, in fact, the biggest obstacle in regenerative medicine. It is also why
embryonic stems are unlikely to be useful in all but a few therapeutic applications. A transplanted eSC
is, after all, foreign to the recipient and, in many instances, would be rejected.
HpSCs, however, come from parthenotes, cells of the ovum that have shed half their DNA in
preparation for fertilization. With only half the HLA matching points, they are orders of magnitude
easier to immune match than heSCs. Daley himself has speculated that as few as ten hpSC lines could
immune match most of the population.
Even high estimates are that 50 hpSC lines will provide rejection-free stem cell therapies for the vast
majority of humans. This will dramatically lower the cost of certain types of critical stem cell therapies.
In animal studies, hpSCs have already demonstrated the ability to “engraft” with their transplant host.
This means they were not rejected and became part of the living animal.
ISCO has advanced programs in several areas, notably various tissues of the eyes. These eye tissues, by
the way, are also suitable for chemical sensitivity tests. ISCO is now working to replace the unpopular
and expensive Draize testing procedure with its hpSC corneal spheres. These beautiful little globes
react to irritants as human eyes do, but do not experience pain.
Draize testing, as you may know, requires the application of potentially irritating substances into the
eyes of rabbits and other animals. No one, including the companies required to perform Draize tests,
like the procedure. I expect the ISCO product to be an international blockbuster.
Recently, International Stem Cell Corporation announced, in conjunction with ViaCyte (formerly
Novocell) the successful derivation from hpSCs of enriched cultures of definitive endoderm (DE). DE
can be further developed into pancreas or liver cells to treat or cure liver disease and diabetes.
Banks of hpSC cells, capable of restoring liver and pancreas function with simple injections, will be
created. A patient's cells would be analyzed using a simple test to find the matching hpSC line, much as
we test for blood types. That line's cells, potentiated to become functioning livers or islets of
Langerhans, would be ordered online and delivered to a clinic for the therapy. Even severe diabetes and
liver disease could be cured with off-the-shelf hpSCs.
Last month, by the way, ISCO enrolled the first U.S.-based donor in its program to establish a bank of
clinical-grade hpSCs. Internationally, clinics are coming on line to provide donor oocytes so that ISCO
can develop stem cell therapies for all ethnicities. The pace of this progress continues to accelerate,
driven by increasingly sophisticated scientific tools – supplied via Moore's law.
Let me return then to the subject of public ignorance of science. Specifically, I would like to highlight
this ignorance regarding parthenogenetic stem cells at the highest levels – the committee that wrote the
president's stem cell funding policy change.
I'm sure you remember during the campaign when President Obama promised to rescind limits on stem
cell research. In fact, the NIH specifically emphasized restrictions on hpSC research while lifting
restrictions on less promising embryonic SC research. An uninformed media missed the story almost
completely. Only a few scientific publications noted and criticized the bizarre policy move.
http://stemcells.nih.gov/policy/2009guidelines.htm
5
Ken Aldrich, the biotech entrepreneur who co-founded International Stem Cell Corporation,
characterized the ruling as, “a scientific tragedy,” Also, he said, “It is important to note that the oocytes
from which hpSCs are derived are obtained via procedures approved by hospital review boards and
ethics committees. All donors voluntarily consent to the use of their eggs after very complete disclosure
of how they will be used. Nor do we ever use a fertilized egg, so there is never an ethical risk that a
human life might be destroyed.”
The hpSC funding restrictions are not, incidentally, stopping ISCO. They are, however, moving many
of its programs offshore to more scientifically hospitable countries. Scientists and a leading
ophthalmological company in India, for example, have embarked with ISCO to commercialize hpSC
retinal and corneal tissue products internationally. While I'm pleased for ISCO and bear no grudge to
Indian scientists, American scientists could use those high-paying scientific jobs. American universities
could use the income that comes from collaborations with biotech firms.
[John here – this tragedy is quite common in my research. Our regulatory rules are way behind the
technology. Guys like Mike West (below) and ISCO simply are not going to wait around. The US is
losing the very jobs that are in fact the best and newest tech. So sad. And angering.]
ISCO appears to be on track to becoming the first profitable stem cell company, largely because of its
subsidiaries Lifeline Cell Technology and Lifeline Skin Care. Lifeline's key players were part of the
core team of skin cell scientists that built the leading skin cell product supplier, Clonetics. Clonetics'
early breakthroughs in the growth of skin cells for burn victims led the way for technologies now used
to grow stem cells.
Lifeline has played a key role in another product that is doing increasingly well for ISCO – Lifeline
Skin Care. This product was discovered originally when researchers applied leftover growth medium,
containing messaging molecules expressed by hpSC skin cells, to their own faces. They noticed that the
appearance of their skin improved, ISCO’s therapeutic scientists got involved, and one thing led to
another. My wife tried an early version with amazing results. The result is that a “cosmeceutical” skin
cream product called Lifeline Skin Care is now sold. Extracts of human parthenogenetic stem cells are
encapsulated into nano-spheres to preserve their potency and enhance bio-delivery to the user.
Full disclosure: I'm proud to have played a minor role in convincing ISCO to market the product. I also
helped establish an independent company, helmed by our host John Mauldin, to market and sell that
product. Revenues are assisting ISCO research in far more important areas, including hpSC liver and
retinal cells. If trends continue, ISCO will be cash-flow positive in the near future.
My involvement helping launch the company that markets ISCO skin care products eventually led to
the decision to stop covering ISCO in my official capacity at Agora Financial. Out of concern that it
would be seen as a conflict of interest, I no longer write about the company for my subscribers. I'm
writing today about the state of regenerative medicine, however. Unlike most of the media, which is
ignoring this important technology, I believe it's impossible to describe stem cell science without
including hpSC science.
If you are interested in learning more about the skin care product (and you probably should be if you
are of a “certain age” and like to keep appearances up, so to speak), you can go to
www.lifelineskincare.com/antiagingbreakthrough to learn about the products that these scientists in
pursuit of curing diseases discovered to rejuvenate your skin) or directly to the website at
6
www.lifelinskincare.com to learn more about the science. Use product code “life4” to get a discount.
[John here: let me echo my enthusiasm for Lifeline Skin Care. We have had so many excellent
responses and feedback from people who have used it!]
Induced Pluripotent Stem Cells and Moore's Law
The other type of pluripotent stem cells that I mentioned above is iPS or induced pluripotent stem cells.
When discussing iPS cells, you have to talk about Dr. Michael West, widely regarded as the father of
regenerative medicine.
West founded Geron but moved on when the company focused on spinal cord injuries. Intent on
developing stem cell therapies for cardiovascular disease, which he saw as both easier and more
important, he turned Advanced Cell Technology into a major stem cell company. He did not, however,
manage the company following its IPO. Once again, differences regarding company goals led him
eventually to move on to continue pursuing cardiovascular regeneration.
After buying rights to important IP he created at Advanced Cell Technology, he turned blood products
company BioTime Inc. into the leader in iPS cell technology. Already, BioTime has a quiver of
accomplishments, including the first stem cell company agreement with big pharma, Israel's Teva. He
acquired the world's first bank of clinical grade human embryonic stem cells created by the government
of Singapore and has put in place dozens of collaborations in California with researchers funded by
California's $3 billion stem cell program.
Subsidiaries exist in Singapore, China and Israel with focuses on various fields, including orthopedics,
cancer and ophthalmology. A particular coup was the defection of Arnold Caplan, Ph.D., a founder of
Osiris Therapeutics and BioMimetics Pharmaceuticals to West's point-of-view on pluripotent stem
cells. Widely considered the father of adult stem cell medicine, Caplan is now the chief scientific
officer of subsidiary OrthoCyte Corporation.
OrthoCyte's first product to market will probably be a device for reconstructive surgery, HyStem-Rx.
This is an implantable cell matrix technology in which stem cells engraft to form 3-dimensional tissues.
The company is going for Europe's CE Mark for medical devices, which can be attained in far less time
than FDA approval.
By far the most interesting of BioTime's subsidiaries, however, is ReCyte Therapeutics. The current
culmination of West's career, ReCyte is located in BioTime's northern California headquarters so West
can be personally involved developing iPS therapy for large-scale cardiovascular and immune system
regeneration.
The company's clearly stated mission statement is to “reverse the developmental aging of human cells”
for “age-related cardiovascular and blood disorders.” This market approaches $1 trillion world-wide as
it is the leading cause of death in most industrialized countries. It is amazing that with all the interest
regenerative medicine has attracted in the medical community that the disproportionate size of this
application wasn't more appreciated by BioTime's competition.
No one suffers more from the lack of accurate public knowledge than West. The best example of this
knowledge gap is in the routine misreporting about the origins of iPS technology.
7
Professor Shinya Yamanaka is usually given credit for discovering that the introduction of certain
genes into a cell will initiate a transformation of that cell into an iPS cell. While Yamanaka's work
demonstrating this effect is certainly important, West applied for a patent on the process before
Yamanaka. He did so in August 2005 while he was chief scientist at ACT and has bought rights to the
technology since moving to BioTime.
I've asked West why he has never challenged accounts of the iPS discovery but he's expressed only an
interest in maintaining rights to perform the process for therapeutic processes. There are several aspects
to West's discovery of the iPS transformation process that we need to understand, however. The first is
that his understanding came about not through the exhaustive experimentation that Yamanaka and his
team performed. Rather, it was a realization based on his profound understanding of human cells.
More importantly, West explained to me several years ago that the Yamanaka procedure, using viruses
to deliver genes, is a medical nonstarter. Researchers using the technique have assumed that, once
viruses have altered the host cell's DNA, they would be inactive. This was a dubious assumption for
several reasons that are now becoming clear to everyone. BioTime's technology circumvents these
problems and was designed to be utilized on an industrial scale.
West told me once, in fact, that it's always been clear that genes produce RNA, which produce proteins
so any of the three can be used to reprogram cells. Clear to him, I suppose. The important point is that
he launched ReCyte to commercialize the process of creating endothelial precursor stem cells from a
donor's own iPS cells. Those endothelial precursors will reverse the telomere clock of cellular aging in
the recipients cardiovascular and eventually immune system. This will not just prevent heart disease, it
will extend your cardiac warranty by as much as a hundred years. For most people, who are more likely
to die of heart disease than any other cause, this will translate into decades of additional healthy life.
If this seems startling to you, I'll tell you again how it has come to pass. Think back to the year 2000. It
doesn't seem that long ago but in scientific terms, it is ancient history thanks to Moore's law. West said
recently that, thanks to exponentially increasing computer power, his research is now progressing 1,000
times faster than it did only ten or fifteen years ago.
I asked him to elucidate and he wrote in an e-mail, “One example is the power of Microarrays. Inspired
by the miniaturization in electronic microchips (really amazing advance compared to the electronics I
played with as a boy), researchers put thousands of DNA sequences on chips. Since the most important
way human biology is regulated is at the level of gene expression, (i.e. A gene is on when it makes
RNA) and this process of regulating gene expression controls all of development, aging, and disease
like cancer.
“This microarray technology allows us to look at virtually every gene and read off whether it is on or
off in every cell type in the body. With ACTCellerate, and using the chips we use at BioTime, it allows
us to quickly do 47,329 different probes for expressed genes and determine conditions to turn say
primitive cells that form the lower jaw into cartilage, bone, or the dentin of the tooth, or map out the
complete profile of the cells of the developing brain. Just studying one gene would have taken a week
15 years ago.
“Now we can easily do a dozen experiments x 47,329 = >500,000 data points. This combined with
computer programs that go though this data to capture important intellectual property for patent filings,
means a flood of new patent claims pending for hundreds of diagnostics and therapeutics. Again, 15
years ago this could be done but >1,000 times slower and therefore at much greater cost. BioTime can
8
therefore do all this with powerful computers and a small staff.
“Also, it is now possible to sequence the entire DNA for a few thousand dollars. Over 1,000 human
genomes have already been sequenced. This will allow scientists to correlate these complete sequences
with all the traits of disease and dramatically expand our understanding of the causes of disease. While
not every disease has a genetic cause, many do, and at minimum, genetics plays some role in virtually
every disease.
“This has led to a Niagara Falls of data. That is why people should not judge the future of medicine by
the past. You haven't seen anything yet.”
Unfortunately, many people are still stuck in the 20th Century. A few weeks ago, a UCSD study
published in the journal Nature cast serious doubt on the usefulness of iPS cells created using the
"Yamanaka technique." Specifically, the study showed that some Yamanaka iPS cells do not "engraft."
That means simply that they were rejected by the host animals. An uninformed press, both scientific
and financial, declared a virtual end to iPS science.
Worse, though BioTime has never relied on Yamanaka's virus technology, the UCSD study was
exploited by short attackers who have been trying to force down BioTime stock prices. BioTime is
currently trading at about half of its recent highs.
Biotechs are a particularly attractive target for short attacks precisely because so few people actually
understand the science behind them and it is an easy shot to point out their lack of revenues. Biotech
companies are typically not valued on current revenues given the timelines of FDA approvals, but
rather on the value of the technology and the demonstration that the management team are able to meet
their developmental milestones.
With a few well-placed rumors, it is often possible to drive down the stock of a scientifically
complicated company, which is how short sellers make their money. These attacks are often wellorchestrated,
especially if a company's stock rises more than expected. Then we can see all-out-war as
a short squeeze nears. http://www.businessdictionary.com/definiti...rt-squeeze.html
The attack on BioTime was, in fact, somewhat successful. Some of the float panicked though
institutional investors have not. It was ironic because only one day before the Nature iPS article was
published, a study performed by Johns Hopkins scientists that proved successful engrafting of iPS cells
was published by GEN: Genetic Engineering & Biotechnology News. It doesn't say so in the GEN
article, but the Johns Hopkins iPS cells were also created using viruses.
Here is a key paragraph from the article: “Researchers have demonstrated that mature and immature
liver cells generated from induced pluripotent stem cells (iPSCs) derived from multiple adult cell types
are as effective as both embryonic stem cell (ESC)-derived hepatocytes and primary human
hepatocytes at engrafting and functioning in the livers of experimental mice. The Johns Hopkins
University School of Medicine team that carried out the studies say iPSC-derived cells were equivalent
to the ESC-derived cells and primary hepatocytes in terms of their capacity to regenerate damaged
livers and with respect to the levels of human-specific liver proteins they secreted into the animals’
bloodstreams.
No one, however, was talking the good news up on the bulletin board rumor mills. I am beginning to
agree with Cramer that unscrupulous short attacks need to be punished. At the very least, they should
9
be prohibited from ever using the technologies of the companies they attack.
Fighting the “Stupid Virus” Pandemic
The chasm between the actual state of the science and the public's perception of science puts more than
money at risk. Lives are endangered by the inability of public institutions to deal with the new pace of
scientific progress.
A prime example can be found in the anti-virus arena. We know another influenza pandemic will
emerge in the next few years. Massive resources are therefore being spent to prepare for this
inevitability. Scientists are trying now to predict which flu strains are likely to hit. Companies are
preparing to manufacture enormous quantities of vaccines as quickly as possible.
Vaccinating for rapidly mutating viruses is, however, a fundamentally irrelevant technology.
Unfortunately, few seem to know that there is a far cheaper and more effective solution to influenza.
This technology has come out of advances in nanotechnology and has been enabled by supercomputers.
I'm not speaking theoretically, by the way. The solution for rapidly mutating viruses exists now. The
company that developed it, however, has garnered only a fraction of the attention it deserves.
NanoViricides Inc. creates nanotech constructs made of submicroscopic polymers and biological
ligands. They are called, not coincidentally, nanoviricides. The polymer portion of these constructs are
approximately spherical virus traps. If you can think of a virus as a key that cracks the cellular safe,
imagine ligands as the locks. A biologist would probably prefer “biological signaling molecules.”
Regardless, ligands that match specific virus families are identified using supercomputer simulations.
When attached to the polymers and introduced into the blood stream, these nanoviricides are more
attractive to viruses than actual cells. Viruses enter into the nanoviricides and are dismantled
harmlessly.
If this technology sounds to you like something out of Isaac Asimov's Fantastic Voyage, you're not
alone. When I first began writing about NanoViricides, the top Google search results were organized
attacks on the company. A cottage industry existed that sold so-called reports that offered “the truth”
about the company. Often, I was personally accused by those attacking NanoViricides of helping
perpetrate a scam.
Fortunately, recent collaborations with world-renowned virus researchers has largely ended such
attacks. Already, the company has demonstrated nanoviricides that lure and kill herpes, dengue and
influenza viruses. In the last weeks, animal tests proved an effectiveness at killing influenza viruses
that is orders of magnitude greater than Tamiflu.
All of the most infamous and scary strains of influenza were destroyed by NanoViricides' FluCide. Any
future mutation of these viruses will also be destroyed. This technology, if it were approved and
distributed widely, would allow us to stop worrying about influenza. At the first indication of the flu, a
nanoviricide injection, skin patch or nasal spray would end flu symptoms within a few hours, no matter
how lethal the virus is in nature.
Because naBiotech and the Unintended Consequences of Moore's Law
By Pat Cox, Editor
Breakthrough Technology Alert
Transistor density doubles roughly every two years, as Moore's law attests. Information technology
therefore advances exponentially. You don't even have to know what a transistor is to feel the impact of
this extraordinary phenomenon. Mobile computing is an example. From new phone features and tablets
to the bandwidth that connects them to the cloud, the innovation is dizzying.
2
Elsewhere, however, even greater advances are being enabled by exponential improvements in
processor power. I'm referring to biotechnology but not just high-tech medical gadgets, though they do
exist.
Echo Therapeutics is a great example, with a device on track for approval that will replace hypodermic
needles in many medical applications. Smaller than an electric toothbrush, the transdermal skin
permeation device utilizes integrated circuits and sensors to painlessly remove the top dead layer of
skin using microdermabrasion. With direct access to the epidermis, drugs can be infused with
absolutely no discomfort. Analytes such as glucose, lactic acid or drug levels can be measured and
transmitted to anybody with a cell phone or mobile device.
Echo Therapeutics' first customers will be hospital staff who will use the technology to quickly
anesthetize needle sites in preparation for transfusion or blood extraction. Cosmetic surgeons, however,
want this technology to quickly prepare patients for dermal filler and Botox procedures.
Combined with a dollar-sized sensing wafer that attaches to the skin, the technology can be used to
provide continual needle-free glucose and other analyte monitoring. Real-time readings can be sent
wirelessly to a medical display or phones belonging to doctors, nurses, parents or the users themselves.
While this continual needle-free technology will make outpatients' lives more pleasant and healthier,
the biggest impact is likely to be on both the cost and quality of hospital care.
Continual glucose monitoring would cut hospital costs by freeing several hours of the average nurse's
day from tedious manual blood sugar testing. More importantly, studies indicate that close observation
and control of glucose levels in hospitals improves every indicator, from costs, length of stay and
mortality, by about a third. Given the serious need to manage health care expenditures, this cost-saving
manifestation of Moore's law will have a dramatic beneficial impact on health care.
Moore's law is yielding far greater benefits in regenerative or stem cell medicine, the only technology
capable of directly addressing age-related degenerative disease. Breathtaking advances are taking place
daily in stem cell science thanks to advances in bioinformatics, the application of statistics and
mathematics to cellular biology via information processing.
Ironically, however, almost no one knows about this accelerating revolution. Many, in fact, deny it. For
that reason, I'm providing an update of the two stem cell companies I consider most important.
Outside of the biotech community, advances are consistently underestimated. Many factors contribute
to this lack of public understanding. To begin with, the details of biotech are simply intimidating to
most people. The basics of computing, by contrast, are actually quite simple. With a little effort, nearly
anybody can grasp those basics. Since the first integrated circuits were created in the 1950s, most
progress in computing has come from engineering smaller, faster components.
The complexity of the biological sciences, on the other hand, dwarfs computer science. This isn't
surprising. There are more switches in one human brain than all the computers in the world. The cells
in only one person's body contain more information, encoded in DNA, than all the information
accessed by Google – by many orders of magnitude. No single scientist today is capable of staying
current in the many esoteric areas of the biological sciences.
This complexity, however, contributes to a huge gap between the public's understanding of biotech and
3
the actual state of the science. There are other factors at work as well. Foremost are two enormous
labyrinthine agencies, the FDA and the SEC. Both of these regulatory bodies monitor and restrict what
biotech firms can tell the public. These limitations may be benign in intent but they impede the flow of
information.
Typically, the public hears about new biotechnologies only when they achieve regulatory approval and
come to market. Winning approval for a drug or device, however, is an enormously expensive and
drawn out process.
As a result, most biotech products coming to market today are five to ten years old. Some are much
older. If personal computing had to jump the same kind of preclinical and clinical hurdles as biotech
companies, we would still be using computers the size of suitcases with cathode ray tube monitors. The
latest phones would do little more than provide intermittent voice communication.
Information about new biotechnologies is further limited by researchers themselves. Those working on
emerging technologies may not want to attract competitors by trumpeting accomplishments.
Even when private sector and academic researchers want to get word out about a new technology, they
often cannot find journalists capable of understanding and telling their stories. Financial distress in the
publishing business has exacerbated this problem.
The bottom line is that widely-held opinions about biotech are often very wrong. These
misconceptions, in turn, often have serious consequences. I'll give you several examples involving the
two stem cell companies I referred to before, BioTime, Inc. and International Stem Cell Corporation as
well as a nanomedicine firm, NanoViricides, Inc.
The Case of the Missing Parthenogenetic Stem Cells
When discussing stem cells, most commentators talk about three stem cell types. The first is adult stem
cells, which have proven disappointing to researchers. Their potential to become different cell types is
limited and they are as old as the donor. The other two stem cell types commonly discussed are both
pluripotent stem cells, meaning they do not age and are capable of becoming any cell type. These are
embryonic stem cells (heSCs) and induced pluripotent stem cells (iPSCs). There is, in fact, an
extremely important third form of pluripotent stem cell.
These are human parthenogenetic stem cells (hpSCs). International Stem Cell Corporation, usually
referred to by its acronym ISCO, pretty much has this stem cell type to themselves because they
developed the technique for creating parthenogenetic stem cell lines and own the intellectual property
governing those processes. This is a very good position to be in because hpSCs have distinct
advantages in many medical procedures.
Parthenogenetic stem cells are derived from unfertilized human oocytes (eggs). This negates the
concerns of those who believe that the use of embryonic stem cells is unethical. There is no shortage of
oocytes because they are collected and discarded routinely in normal fertilization procedures.
Among the leading scientists who have studied and validated the therapeutic potential of hpSCs is
George Daley, MD, PhD. Daley is Professor of Biological Chemistry and Molecular Pharmacology at
Harvard and Director of the Stem Cell Transplantation Program at Children's Hospital Boston.
4
His journal article, “Histocompatible Embryonic Stem Cells by Parthenogenesis,” describes another
reason researchers are interested in hpSCs. Histocompatability refers to ability to avoid immune
rejection. Immune rejection is, in fact, the biggest obstacle in regenerative medicine. It is also why
embryonic stems are unlikely to be useful in all but a few therapeutic applications. A transplanted eSC
is, after all, foreign to the recipient and, in many instances, would be rejected.
HpSCs, however, come from parthenotes, cells of the ovum that have shed half their DNA in
preparation for fertilization. With only half the HLA matching points, they are orders of magnitude
easier to immune match than heSCs. Daley himself has speculated that as few as ten hpSC lines could
immune match most of the population.
Even high estimates are that 50 hpSC lines will provide rejection-free stem cell therapies for the vast
majority of humans. This will dramatically lower the cost of certain types of critical stem cell therapies.
In animal studies, hpSCs have already demonstrated the ability to “engraft” with their transplant host.
This means they were not rejected and became part of the living animal.
ISCO has advanced programs in several areas, notably various tissues of the eyes. These eye tissues, by
the way, are also suitable for chemical sensitivity tests. ISCO is now working to replace the unpopular
and expensive Draize testing procedure with its hpSC corneal spheres. These beautiful little globes
react to irritants as human eyes do, but do not experience pain.
Draize testing, as you may know, requires the application of potentially irritating substances into the
eyes of rabbits and other animals. No one, including the companies required to perform Draize tests,
like the procedure. I expect the ISCO product to be an international blockbuster.
Recently, International Stem Cell Corporation announced, in conjunction with ViaCyte (formerly
Novocell) the successful derivation from hpSCs of enriched cultures of definitive endoderm (DE). DE
can be further developed into pancreas or liver cells to treat or cure liver disease and diabetes.
Banks of hpSC cells, capable of restoring liver and pancreas function with simple injections, will be
created. A patient's cells would be analyzed using a simple test to find the matching hpSC line, much as
we test for blood types. That line's cells, potentiated to become functioning livers or islets of
Langerhans, would be ordered online and delivered to a clinic for the therapy. Even severe diabetes and
liver disease could be cured with off-the-shelf hpSCs.
Last month, by the way, ISCO enrolled the first U.S.-based donor in its program to establish a bank of
clinical-grade hpSCs. Internationally, clinics are coming on line to provide donor oocytes so that ISCO
can develop stem cell therapies for all ethnicities. The pace of this progress continues to accelerate,
driven by increasingly sophisticated scientific tools – supplied via Moore's law.
Let me return then to the subject of public ignorance of science. Specifically, I would like to highlight
this ignorance regarding parthenogenetic stem cells at the highest levels – the committee that wrote the
president's stem cell funding policy change.
I'm sure you remember during the campaign when President Obama promised to rescind limits on stem
cell research. In fact, the NIH specifically emphasized restrictions on hpSC research while lifting
restrictions on less promising embryonic SC research. An uninformed media missed the story almost
completely. Only a few scientific publications noted and criticized the bizarre policy move.
http://stemcells.nih.gov/policy/2009guidelines.htm
5
Ken Aldrich, the biotech entrepreneur who co-founded International Stem Cell Corporation,
characterized the ruling as, “a scientific tragedy,” Also, he said, “It is important to note that the oocytes
from which hpSCs are derived are obtained via procedures approved by hospital review boards and
ethics committees. All donors voluntarily consent to the use of their eggs after very complete disclosure
of how they will be used. Nor do we ever use a fertilized egg, so there is never an ethical risk that a
human life might be destroyed.”
The hpSC funding restrictions are not, incidentally, stopping ISCO. They are, however, moving many
of its programs offshore to more scientifically hospitable countries. Scientists and a leading
ophthalmological company in India, for example, have embarked with ISCO to commercialize hpSC
retinal and corneal tissue products internationally. While I'm pleased for ISCO and bear no grudge to
Indian scientists, American scientists could use those high-paying scientific jobs. American universities
could use the income that comes from collaborations with biotech firms.
[John here – this tragedy is quite common in my research. Our regulatory rules are way behind the
technology. Guys like Mike West (below) and ISCO simply are not going to wait around. The US is
losing the very jobs that are in fact the best and newest tech. So sad. And angering.]
ISCO appears to be on track to becoming the first profitable stem cell company, largely because of its
subsidiaries Lifeline Cell Technology and Lifeline Skin Care. Lifeline's key players were part of the
core team of skin cell scientists that built the leading skin cell product supplier, Clonetics. Clonetics'
early breakthroughs in the growth of skin cells for burn victims led the way for technologies now used
to grow stem cells.
Lifeline has played a key role in another product that is doing increasingly well for ISCO – Lifeline
Skin Care. This product was discovered originally when researchers applied leftover growth medium,
containing messaging molecules expressed by hpSC skin cells, to their own faces. They noticed that the
appearance of their skin improved, ISCO’s therapeutic scientists got involved, and one thing led to
another. My wife tried an early version with amazing results. The result is that a “cosmeceutical” skin
cream product called Lifeline Skin Care is now sold. Extracts of human parthenogenetic stem cells are
encapsulated into nano-spheres to preserve their potency and enhance bio-delivery to the user.
Full disclosure: I'm proud to have played a minor role in convincing ISCO to market the product. I also
helped establish an independent company, helmed by our host John Mauldin, to market and sell that
product. Revenues are assisting ISCO research in far more important areas, including hpSC liver and
retinal cells. If trends continue, ISCO will be cash-flow positive in the near future.
My involvement helping launch the company that markets ISCO skin care products eventually led to
the decision to stop covering ISCO in my official capacity at Agora Financial. Out of concern that it
would be seen as a conflict of interest, I no longer write about the company for my subscribers. I'm
writing today about the state of regenerative medicine, however. Unlike most of the media, which is
ignoring this important technology, I believe it's impossible to describe stem cell science without
including hpSC science.
If you are interested in learning more about the skin care product (and you probably should be if you
are of a “certain age” and like to keep appearances up, so to speak), you can go to
www.lifelineskincare.com/antiagingbreakthrough to learn about the products that these scientists in
pursuit of curing diseases discovered to rejuvenate your skin) or directly to the website at
6
www.lifelinskincare.com to learn more about the science. Use product code “life4” to get a discount.
[John here: let me echo my enthusiasm for Lifeline Skin Care. We have had so many excellent
responses and feedback from people who have used it!]
Induced Pluripotent Stem Cells and Moore's Law
The other type of pluripotent stem cells that I mentioned above is iPS or induced pluripotent stem cells.
When discussing iPS cells, you have to talk about Dr. Michael West, widely regarded as the father of
regenerative medicine.
West founded Geron but moved on when the company focused on spinal cord injuries. Intent on
developing stem cell therapies for cardiovascular disease, which he saw as both easier and more
important, he turned Advanced Cell Technology into a major stem cell company. He did not, however,
manage the company following its IPO. Once again, differences regarding company goals led him
eventually to move on to continue pursuing cardiovascular regeneration.
After buying rights to important IP he created at Advanced Cell Technology, he turned blood products
company BioTime Inc. into the leader in iPS cell technology. Already, BioTime has a quiver of
accomplishments, including the first stem cell company agreement with big pharma, Israel's Teva. He
acquired the world's first bank of clinical grade human embryonic stem cells created by the government
of Singapore and has put in place dozens of collaborations in California with researchers funded by
California's $3 billion stem cell program.
Subsidiaries exist in Singapore, China and Israel with focuses on various fields, including orthopedics,
cancer and ophthalmology. A particular coup was the defection of Arnold Caplan, Ph.D., a founder of
Osiris Therapeutics and BioMimetics Pharmaceuticals to West's point-of-view on pluripotent stem
cells. Widely considered the father of adult stem cell medicine, Caplan is now the chief scientific
officer of subsidiary OrthoCyte Corporation.
OrthoCyte's first product to market will probably be a device for reconstructive surgery, HyStem-Rx.
This is an implantable cell matrix technology in which stem cells engraft to form 3-dimensional tissues.
The company is going for Europe's CE Mark for medical devices, which can be attained in far less time
than FDA approval.
By far the most interesting of BioTime's subsidiaries, however, is ReCyte Therapeutics. The current
culmination of West's career, ReCyte is located in BioTime's northern California headquarters so West
can be personally involved developing iPS therapy for large-scale cardiovascular and immune system
regeneration.
The company's clearly stated mission statement is to “reverse the developmental aging of human cells”
for “age-related cardiovascular and blood disorders.” This market approaches $1 trillion world-wide as
it is the leading cause of death in most industrialized countries. It is amazing that with all the interest
regenerative medicine has attracted in the medical community that the disproportionate size of this
application wasn't more appreciated by BioTime's competition.
No one suffers more from the lack of accurate public knowledge than West. The best example of this
knowledge gap is in the routine misreporting about the origins of iPS technology.
7
Professor Shinya Yamanaka is usually given credit for discovering that the introduction of certain
genes into a cell will initiate a transformation of that cell into an iPS cell. While Yamanaka's work
demonstrating this effect is certainly important, West applied for a patent on the process before
Yamanaka. He did so in August 2005 while he was chief scientist at ACT and has bought rights to the
technology since moving to BioTime.
I've asked West why he has never challenged accounts of the iPS discovery but he's expressed only an
interest in maintaining rights to perform the process for therapeutic processes. There are several aspects
to West's discovery of the iPS transformation process that we need to understand, however. The first is
that his understanding came about not through the exhaustive experimentation that Yamanaka and his
team performed. Rather, it was a realization based on his profound understanding of human cells.
More importantly, West explained to me several years ago that the Yamanaka procedure, using viruses
to deliver genes, is a medical nonstarter. Researchers using the technique have assumed that, once
viruses have altered the host cell's DNA, they would be inactive. This was a dubious assumption for
several reasons that are now becoming clear to everyone. BioTime's technology circumvents these
problems and was designed to be utilized on an industrial scale.
West told me once, in fact, that it's always been clear that genes produce RNA, which produce proteins
so any of the three can be used to reprogram cells. Clear to him, I suppose. The important point is that
he launched ReCyte to commercialize the process of creating endothelial precursor stem cells from a
donor's own iPS cells. Those endothelial precursors will reverse the telomere clock of cellular aging in
the recipients cardiovascular and eventually immune system. This will not just prevent heart disease, it
will extend your cardiac warranty by as much as a hundred years. For most people, who are more likely
to die of heart disease than any other cause, this will translate into decades of additional healthy life.
If this seems startling to you, I'll tell you again how it has come to pass. Think back to the year 2000. It
doesn't seem that long ago but in scientific terms, it is ancient history thanks to Moore's law. West said
recently that, thanks to exponentially increasing computer power, his research is now progressing 1,000
times faster than it did only ten or fifteen years ago.
I asked him to elucidate and he wrote in an e-mail, “One example is the power of Microarrays. Inspired
by the miniaturization in electronic microchips (really amazing advance compared to the electronics I
played with as a boy), researchers put thousands of DNA sequences on chips. Since the most important
way human biology is regulated is at the level of gene expression, (i.e. A gene is on when it makes
RNA) and this process of regulating gene expression controls all of development, aging, and disease
like cancer.
“This microarray technology allows us to look at virtually every gene and read off whether it is on or
off in every cell type in the body. With ACTCellerate, and using the chips we use at BioTime, it allows
us to quickly do 47,329 different probes for expressed genes and determine conditions to turn say
primitive cells that form the lower jaw into cartilage, bone, or the dentin of the tooth, or map out the
complete profile of the cells of the developing brain. Just studying one gene would have taken a week
15 years ago.
“Now we can easily do a dozen experiments x 47,329 = >500,000 data points. This combined with
computer programs that go though this data to capture important intellectual property for patent filings,
means a flood of new patent claims pending for hundreds of diagnostics and therapeutics. Again, 15
years ago this could be done but >1,000 times slower and therefore at much greater cost. BioTime can
8
therefore do all this with powerful computers and a small staff.
“Also, it is now possible to sequence the entire DNA for a few thousand dollars. Over 1,000 human
genomes have already been sequenced. This will allow scientists to correlate these complete sequences
with all the traits of disease and dramatically expand our understanding of the causes of disease. While
not every disease has a genetic cause, many do, and at minimum, genetics plays some role in virtually
every disease.
“This has led to a Niagara Falls of data. That is why people should not judge the future of medicine by
the past. You haven't seen anything yet.”
Unfortunately, many people are still stuck in the 20th Century. A few weeks ago, a UCSD study
published in the journal Nature cast serious doubt on the usefulness of iPS cells created using the
"Yamanaka technique." Specifically, the study showed that some Yamanaka iPS cells do not "engraft."
That means simply that they were rejected by the host animals. An uninformed press, both scientific
and financial, declared a virtual end to iPS science.
Worse, though BioTime has never relied on Yamanaka's virus technology, the UCSD study was
exploited by short attackers who have been trying to force down BioTime stock prices. BioTime is
currently trading at about half of its recent highs.
Biotechs are a particularly attractive target for short attacks precisely because so few people actually
understand the science behind them and it is an easy shot to point out their lack of revenues. Biotech
companies are typically not valued on current revenues given the timelines of FDA approvals, but
rather on the value of the technology and the demonstration that the management team are able to meet
their developmental milestones.
With a few well-placed rumors, it is often possible to drive down the stock of a scientifically
complicated company, which is how short sellers make their money. These attacks are often wellorchestrated,
especially if a company's stock rises more than expected. Then we can see all-out-war as
a short squeeze nears. http://www.businessdictionary.com/definiti...rt-squeeze.html
The attack on BioTime was, in fact, somewhat successful. Some of the float panicked though
institutional investors have not. It was ironic because only one day before the Nature iPS article was
published, a study performed by Johns Hopkins scientists that proved successful engrafting of iPS cells
was published by GEN: Genetic Engineering & Biotechnology News. It doesn't say so in the GEN
article, but the Johns Hopkins iPS cells were also created using viruses.
Here is a key paragraph from the article: “Researchers have demonstrated that mature and immature
liver cells generated from induced pluripotent stem cells (iPSCs) derived from multiple adult cell types
are as effective as both embryonic stem cell (ESC)-derived hepatocytes and primary human
hepatocytes at engrafting and functioning in the livers of experimental mice. The Johns Hopkins
University School of Medicine team that carried out the studies say iPSC-derived cells were equivalent
to the ESC-derived cells and primary hepatocytes in terms of their capacity to regenerate damaged
livers and with respect to the levels of human-specific liver proteins they secreted into the animals’
bloodstreams.
No one, however, was talking the good news up on the bulletin board rumor mills. I am beginning to
agree with Cramer that unscrupulous short attacks need to be punished. At the very least, they should
9
be prohibited from ever using the technologies of the companies they attack.
Fighting the “Stupid Virus” Pandemic
The chasm between the actual state of the science and the public's perception of science puts more than
money at risk. Lives are endangered by the inability of public institutions to deal with the new pace of
scientific progress.
A prime example can be found in the anti-virus arena. We know another influenza pandemic will
emerge in the next few years. Massive resources are therefore being spent to prepare for this
inevitability. Scientists are trying now to predict which flu strains are likely to hit. Companies are
preparing to manufacture enormous quantities of vaccines as quickly as possible.
Vaccinating for rapidly mutating viruses is, however, a fundamentally irrelevant technology.
Unfortunately, few seem to know that there is a far cheaper and more effective solution to influenza.
This technology has come out of advances in nanotechnology and has been enabled by supercomputers.
I'm not speaking theoretically, by the way. The solution for rapidly mutating viruses exists now. The
company that developed it, however, has garnered only a fraction of the attention it deserves.
NanoViricides Inc. creates nanotech constructs made of submicroscopic polymers and biological
ligands. They are called, not coincidentally, nanoviricides. The polymer portion of these constructs are
approximately spherical virus traps. If you can think of a virus as a key that cracks the cellular safe,
imagine ligands as the locks. A biologist would probably prefer “biological signaling molecules.”
Regardless, ligands that match specific virus families are identified using supercomputer simulations.
When attached to the polymers and introduced into the blood stream, these nanoviricides are more
attractive to viruses than actual cells. Viruses enter into the nanoviricides and are dismantled
harmlessly.
If this technology sounds to you like something out of Isaac Asimov's Fantastic Voyage, you're not
alone. When I first began writing about NanoViricides, the top Google search results were organized
attacks on the company. A cottage industry existed that sold so-called reports that offered “the truth”
about the company. Often, I was personally accused by those attacking NanoViricides of helping
perpetrate a scam.
Fortunately, recent collaborations with world-renowned virus researchers has largely ended such
attacks. Already, the company has demonstrated nanoviricides that lure and kill herpes, dengue and
influenza viruses. In the last weeks, animal tests proved an effectiveness at killing influenza viruses
that is orders of magnitude greater than Tamiflu.
All of the most infamous and scary strains of influenza were destroyed by NanoViricides' FluCide. Any
future mutation of these viruses will also be destroyed. This technology, if it were approved and
distributed widely, would allow us to stop worrying about influenza. At the first indication of the flu, a
nanoviricide injection, skin patch or nasal spray would end flu symptoms within a few hours, no matter
how lethal the virus is in nature.
Because nanoviricides operate in a biological/mechanical fashion, we don't need to worry that they will
not work in humans. They work anywhere they are encountered by their target viruses. They have
10
virtually no toxicity. They are cheap and have enormously long shelf lives. I would not hesitate to
accept an injection right now. When the next pandemic inevitably arrives, I hope to do just that.
Nevertheless, I often read articles in the popular press about some new discovery that “will one day
make nanotech medicine a reality.” On the contrary. It is a reality now, though we have not yet as a
society understood and implemented this nanotechnology.
This is the unintended consequence of Moore's law. Science is advancing so fast that hundreds of
thousands will probably die unnecessarily before we make the transition from influenza vaccines to
nanoviricides. There is a very real war being fought right now between ignorance and science. Science
will win but it would be nice if it won sooner than later.noviricides operate in a biological/mechanical fashion, we don't need to worry that they will
not work in humans. They work anywhere they are encountered by their target viruses. They have
10
virtually no toxicity. They are cheap and have enormously long shelf lives. I would not hesitate to
accept an injection right now. When the next pandemic inevitably arrives, I hope to do just that.
Nevertheless, I often read articles in the popular press about some new discovery that “will one day
make nanotech medicine a reality.” On the contrary. It is a reality now, though we have not yet as a
society understood and implemented this nanotechnology.
This is the unintended consequence of Moore's law. Science is advancing so fast that hundreds of
thousands will probably die unnecessarily before we make the transition from influenza vaccines to
nanoviricides. There is a very real war being fought right now between ignorance and science. Science
will win but it would be nice if it won sooner than later.
  Forum: By Share Code

arjan1972
Posted on: Jun 22 2011, 08:17 PM


Group: Member
Posts: 135

CUV left the Xetra trading months ago. As far as i know CUV stays avalaible over the Frankfurt Exchange. So if you have a german Stock Account it's no problem.

  Forum: By Share Code

arjan1972
Posted on: Jun 6 2011, 09:49 PM


Group: Member
Posts: 135

it's good to see that multiple drug companies are developing medicine to treat melanoma (with good results). No cure yet but a possible way to live longer and a chance to experience a real cure in the middle- long future. That if the authorities help to speed up the approval process.
at least as important is the prevention of skin cancer. Maybe that Scenesse is going to play an important role in that part. It sure has the potential. The good thing about it, it might be not that far away from approval
  Forum: By Share Code

arjan1972
Posted on: Oct 14 2010, 06:31 AM


Group: Member
Posts: 135

Looks like the largest CUV Holder has some 'new' old problems to solve in the US.

http://4closurefraud.org/

1 JP MORGAN NOMINEES AUSTRALIA LIMITED <CASH INCOME 40,015,630
2 ANZ NOMINEES LIMITED <CASH INCOME A/C> 32,312,519
3 NATIONAL NOMINEES LIMITED 30,752,871
4 CITICORP NOMINEES PTY LIMITED 19,053,445
5 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 16,429,829
6 SANDHURST TRUSTEES LTD <JMFG CONSOL A/C> 13,617,071
7 BOODUP NOMINEES PTY LTD <OTTER SUPER FUND A/C> 6,666,426
8 MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED 4,147,205
9 J P MORGAN NOMINEES AUSTRALIA LIMITED 2,240,299
10 HEADSTART GLOBAL HOLDINGS LTD 1,990,665


  Forum: By Share Code

arjan1972
Posted on: Oct 10 2010, 03:43 AM


Group: Member
Posts: 135

Here a comment to SADIF from our friend Uhohinc (Yahoo Board)

http://sadifanalytics.com/stockmarks/abo...
SADIF has no credability in my opinion for unlimitied reasons, and nor does it's report released the same day as clinuvels annual.
SDIF is new, and attempting to raise capital itself,it is attempting to sell subscriptions. The author of all the 16,000 reports is one of the two partners with his phone number to his house on the report. It has zero employees. The "professor" whom runs it out of Portugal in his home claims to have 30 years experience. (you would think he would be able to use his own trademarked analytical propriatary program to have made enough money to not need to seek money online for more partners) It claims a better investment analyst platform, but they all do. The timing of the release is to take advantage of interest at the release by the company of it's annual, which was clever. Reminds me of that old computer programmer adage "garbage in, garbage out" His report states Clinuvels closest peerlike company is OBJ limited for which its summary claims is just as badly equal to Clinuvel, which he says Clinuvel is similar to, but SDIF's report for OBJ Limitied in March gives a summary with much more positive words in OBJ but no Clinuvel peerage. This program and SDIF reports are boiler plate fill in the blanks with simplistic basic computer boolean logic with anyones guess at what alogrythems or how SDIF turns subjective itrinsic abstracts and cognitive conceptualizations into SDIF numbers that then put out Cliche words to describe the present and future of any company. Technicals and patterns of recognition do not work in a one drug not approved small company..........It either gets approved or not, with alot of subjectivity and objectivity that can not be numbers crunched in SADIF "garanteed" and "proven" claim at its small print. Just look at the reputable analytical company reports that have predicted stock price ten times Clinuvel's stock price long ago. SDIF compared Clinuvel to under performing its peer PROGEN, which has no drug in phase III, has a completely different market potential, competitor drugs, etc... to the infinites. SDIF is not getting any more or better information and definitely any secret privilidged information than we get about Clinuvel. I suggest SDIF is merely downloading every metric on the daily stock trade pages and creating a marketing gimmick. It took me two hours to read Clinuvel's report last night, how can two guys read 16,000 reports and affiliated data and company profiles that are all fed by the companys and have a valid report. All the words all the reports use are ambiguous and pull the safe harbor do not really believe or hold the report writer accountable legal for any thing said or inferred. And then how does a SDIF program discern a human trait that computers are not powerful enough yet to recognize, lies, decietful claims or statements, misinformation, disinformation, or mistakes said or left out, just look at hundreds of companys that managements just sap the money away and then de list. The same Carl Spana running PTn has run two other biotechs out of money in his history, but has never put out a negative press release. SLA on the asx is artfully dancing a game with pine tree needle extracts claiming it wants to build its market befor getting FDA clinical trials done........and raising and spending money !!!!!!!!!
And for many other reasons I give no value to SDIF report, but many others will no matter.
  Forum: By Share Code

arjan1972
Posted on: Oct 9 2010, 12:18 AM


Group: Member
Posts: 135

Dear Shane, the question about SADIF was rhetorical wink.gif I mean, who are they? how important is a report from this company?
  Forum: By Share Code

arjan1972
Posted on: Oct 8 2010, 11:28 PM


Group: Member
Posts: 135

I am in this Stock since 2005, i still believe in it. No Stress here.. I am still buying more shares at this ridiculous SP

and by the way, wtf is Sadif for a company?
  Forum: By Share Code

arjan1972
Posted on: Oct 8 2010, 08:38 PM


Group: Member
Posts: 135

oh great, another 'sign'. There is not much trust in this company, just a few fanatics (including me) who really believe in the product. The big question was and is if the management can get this baby on the shelves. The smart money is obviously betting against it.
  Forum: By Share Code

arjan1972
Posted on: Feb 8 2010, 04:53 PM


Group: Member
Posts: 135

Rpape,

Page 2, todays Newsletter

'The ability to provide a treatment for these adult patients is meaningful, and we anticipate that Clinuvel will also be able to provide treatment for children in the near future.'
  Forum: By Share Code

arjan1972
Posted on: Dec 31 2009, 02:39 AM


Group: Member
Posts: 135

i am out of the rollercoaster (for a week;-)) Tomorrow i am in Ischgl/Austria, Skiing. I wish you all a good new Years Party and lot's of luck and health in 2010!
  Forum: By Share Code

arjan1972
Posted on: Dec 30 2009, 02:23 AM


Group: Member
Posts: 135

hey.. and plus 18% in Frankfurt today... back @ 0,19 cents. weirdsmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Dec 28 2009, 07:24 PM


Group: Member
Posts: 135

CUV down 10% in Frankfurt.. 0,16 cents. (on a 7000,- Euro deal) Sometimes i ask myself.. why? Why do i stick on this?
If this isn't a love/hate relationship..what is?

I guess 2010 is going to show us if the Love is mutual

  Forum: By Share Code

arjan1972
Posted on: Dec 27 2009, 07:19 AM


Group: Member
Posts: 135

i think it's quite disturbing that almost all these new stories also refer to doctors warning for possible immune system problems. I never heart of this possibility.
  Forum: By Share Code

arjan1972
Posted on: Dec 6 2009, 10:42 PM


Group: Member
Posts: 135

several Invest Websites report that Clinuvel is the hot bet for the coming weeks..




http://www.deraktionaer.de/xist4c/web/Doug...d_11153689_.htm
Trend Invest Report: Heiße Wette auf gute Phase-III-Daten

Bei der australischen Biotech-Schmiede Clinuvel (WKN A0J EGY) werden dem Trend Invest Report zufolge, noch vor Jahresfrist die "Karten auf den Tisch" gelegt. Das Unternehmen, welches sich auf die Erforschung von Wirkstoffen gegen schwere Hauterkrankungen spezialisiert hat, will für seinen am weitesten fortgeschrittenen Medikamentenkandidaten Afamelanotide noch in diesem Jahr Phase-III-Daten vorlegen, und zwar in der Indikation "Erythropoetische Protoporphyrie" (EPP). Hinter dem schwer auszusprechenden Namen verbirgt sich eine Stoffwechselstörung, die sich negativ auf die Blutbildung auswirkt. Das wiederum zeigt sich in einer schweren Lichtunverträglichkeit, die das Leben der Patienten stark einschränkt. Eine wirksame Therapie gibt es bislang nicht. Die Experten raten zum spekulativen Einstieg mit einer kleinen Position.

Invest Trend Report: Hot betting on good Phase III data (google Translation)

In the case of the Australian biotech Clinuvel (TSX A0J EGY) the Invest Trend Report thinks that till end of this year, the "cards must be on the table" . The company, which specializes in the study of drugs for severe skin diseases, will present for its most advanced drug candidate Afamelanotide this year Phase III data, in the indication "Erythropoietic protoporphyria (EPP). Behind the hard to pronounce name is a metabolic disorder that affects negatively to the blood. This in turn is reflected in a serious intolerance to light, which greatly restricts patients' lives. Effective treatment is in place. The experts advise to start with a small speculative position.
  Forum: By Share Code

arjan1972
Posted on: Nov 30 2009, 09:23 AM


Group: Member
Posts: 135

this will help to slow down the cash burn rate..
  Forum: By Share Code

arjan1972
Posted on: Nov 25 2009, 01:39 AM


Group: Member
Posts: 135

i must say that it shocks me that good informed guys like you Uhohinc are in fear right now. I mean, what is new? We al knew and know that Clinuvel is very risky. We all knew and know that Clinuvel is not a very good communicator and tend to break their selfmade timelines time after time. The Product is a potential Blockbuster but the chance that they get the Product on the shelf is small and it's very possible that Clinuvel is bankrupt in one year from now.. and that is the reason you can make a fortune if you dear to invest right now.. and win. Most of us know that..

(IMO) It is a kind of gambling, for sure. Nobody wants to hear it but that's accectly what it is..

Oh, by the way.. i am still in. The game just started..
  Forum: By Share Code

arjan1972
Posted on: Oct 21 2009, 05:00 PM


Group: Member
Posts: 135

Maybe. Never got the annual report by post. Maybe it's for the agm invitation.
  Forum: By Share Code

arjan1972
Posted on: Oct 21 2009, 07:54 AM


Group: Member
Posts: 135

just got a letter from my Bank/Broker (Germany). It says that Clinuvel asked for names and addresses of all CUV holders. Does somebody of you guys know why they need this data?
  Forum: By Share Code

arjan1972
Posted on: Aug 20 2009, 02:45 PM


Group: Member
Posts: 135

Good Morning X-Ray,

did i mis something? Why Today?
  Forum: By Share Code

arjan1972
Posted on: Jun 10 2009, 05:25 PM


Group: Member
Posts: 135

i hope you're right. The succes of Botox crossed my mind too. Though there is difference, the alternative to botox is plastic surgery. The alternative for a lot of Cosmetic CUV Users is the Tan Salon.
  Forum: By Share Code

arjan1972
Posted on: Jun 10 2009, 05:38 AM


Group: Member
Posts: 135

a topical formulation for CUV is in my opinion necessary to get to realy big sales. The logical real next Milestone - when finally approved. It would surprise me if they stopped that research.
  Forum: By Share Code

arjan1972
Posted on: Jun 9 2009, 10:13 PM


Group: Member
Posts: 135

i remember that Clinuvel (in Epitan times) started to develop a topical formulation for Melanotan, based on the Restoraderm topical drug delivery technology. Partner in this matter was (or is) CollaGenex Pharmaceuticals.

Does anybody know the status Quo of this projekt? Is it still alive?
  Forum: By Share Code

arjan1972
Posted on: May 23 2009, 05:56 AM


Group: Member
Posts: 135

http://www.forexyard.com/reuters/popup_reu...ATE-1-INTERVIEW
  Forum: By Share Code

arjan1972
Posted on: May 16 2009, 06:25 PM


Group: Member
Posts: 135

and in the same Sun:

http://www.thesun.co.uk/sol/homepage/showb...icle2432611.ece

Jacko with Skin Cancer..
  Forum: By Share Code

arjan1972
Posted on: May 5 2009, 07:14 AM


Group: Member
Posts: 135

You may call me El Blindo from now cool.gif .. I checked the numbers, there was a total volume of 663.000 / > 162.000 Euro that is certainly more than the average on the DAX. Excusez Moi
  Forum: By Share Code

arjan1972
Posted on: May 5 2009, 02:23 AM


Group: Member
Posts: 135

no answers, no official Statement on the Site (yet). Not a extreme high Volume either. A normal day until 16:27. Some big buys and the SP jumps from 0.17 to 0,29 (!) Cents.

Tick Data
TimePrice in €Price ExtensionTraded Units 17:35:59 0.230
4,454 17:30:49 0.230
- 17:30:17 0.230
2,500 17:20:17 0.240
8,046 17:20:08 0.240
5,000 17:13:21 0.240
4,000 17:12:54 0.240
5,000 16:56:31 0.25
5,000 16:45:39 0.25
6,000 16:45:09 0.25
14,000 16:42:56 0.27
5,000 16:41:15 0.27
14,000 16:38:29 0.28
5,000 16:37:33 0.26
6,000 16:37:30 0.28
5,000 16:35:50 0.240
20,000 16:31:30 0.25
7,954 16:30:26 0.29
16,500 16:30:20 0.29
20,000 16:30:19 0.29
40,000 16:30:13 0.29
10,000 16:30:08 0.29
5,000 16:29:47 0.29
50,000 16:29:39 0.29A122,000 16:29:17 0.29
- 16:29:02 0.29
- 16:28:57 0.29
- 16:28:56 0.29
- 16:28:50 0.29
- 16:28:49 0.29
- 16:28:08 0.29
- 16:27:36 0.29
- 16:27:18 0.29
- 16:27:17 0.220
28,500 16:27:17 0.218
8,000 16:27:17 0.200
10,000 16:27:17 0.190
2,500 16:27:17 0.182
40,000 16:27:17 0.178
30,000 16:27:17 0.175
17,500 12:36:43 0.170
20,000 11:09:04 0.170
30,000 09:04:03 0.175E2,500
  Forum: By Share Code

arjan1972
Posted on: Apr 23 2009, 09:43 PM


Group: Member
Posts: 135

http://www.asx.com.au/asxpdf/20090423/pdf/31h69kjbs302mx.pdf
  Forum: By Share Code

arjan1972
Posted on: Apr 6 2009, 02:08 AM


Group: Member
Posts: 135

Finaly some important news..
  Forum: By Share Code

arjan1972
Posted on: Mar 29 2009, 05:00 AM


Group: Member
Posts: 135

be aware of what? Could you be a little more specific (?)
  Forum: By Share Code

arjan1972
Posted on: Feb 11 2009, 11:19 PM


Group: Member
Posts: 135

1) If available, would you consider using afamelanotide either for cosmetic or purely medical reasons?
Answers:

YES

2) Do you know other people that would consider using afamelanotide either for cosmetic or purely medical reasons?
Answers:

YES

3) Are you planning to buy or sell shares in the coming month or do you not expect to trade any?
Answers:

NOT
  Forum: By Share Code

arjan1972
Posted on: Jan 22 2009, 01:37 AM


Group: Member
Posts: 135

QUOTE (rabbitrun @ Wednesday 21/01/09 03:39pm)

yep, the article is confusing MT2 with afamelanotide.. Anyway, those people and this sort of press ruins the image of afamelanotide. Imagine the stupidity. How can you be so dumb.. Injecting some stuff into your body not knowing what it is and how to dose it just to get a tan and to look healthy..
You might expect them to do some research first, at least!

Another good reason to approve afamelanotide as soon as possible so those Idiots can get it from their Doctor and do not hurt themselfes anymore. devilsmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Jan 21 2009, 07:53 AM


Group: Member
Posts: 135

In reply to: Rosewood on Tuesday 20/01/09 11:50pm

lmaosmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Jan 14 2009, 05:35 PM


Group: Member
Posts: 135

QUOTE (ognid @ Wednesday 14/01/09 05:14am)

Ognid, can you tell us the reason to get out now. Don't get me wrong but there are some indications for good news..

Thanks anyway & good luck
  Forum: By Share Code

arjan1972
Posted on: Dec 25 2008, 07:23 PM


Group: Member
Posts: 135

Clinuvel Zurich is stocking up, they are looking for a Clinical Research Associate, This is our chance to get somebody inside cool.gif


Arbeitgeber Clinuvel AG
Ort Zurich
Stellenbeschreibung

KEY RESULT AREAS

Study Feasibility Assessments


* Liaise with internal and external experts regarding proposed protocol scope, budget and timelines

* Identification, assessment and selection of appropriate investigators/sites and other service providers according to project requirements and company SOPs
Clinuvel Zurich is looking for a

Study Set-up


* Ensure site feasibility and preparation and execution of study initiation and associated meetings


Investigational Medicinal Product & Study Supplies


* Ensure all study materials including investigational medicinal products are procured appropriately and available on site when required

* Ensure all labeling requirements are met

* Assist in securing import documentation if necessary

* Arrange adequate storage and dispatch of investigational medicinal product and study materials to the investigational site


Document Management


* Collect and compile Essential Documents (according to ICH GCP guidelines and company SOPs)


Ethics Committee Documentation


* Prepare required HREC/IEC applications in a timely manner


Study Site Staff


* Train study staff in all study related processes / procedures

* Coordinate meetings with investigator as study site staff


Monitoring


* Monitoring the progress of clinical trials through regular visits and correspondence to ensure satisfactory conduct of trials including:
- monitor recruitment and consenting procedures
- adherence to the study protocol
- completion of CRFs and review of source data
- collection of data as specified in project plans
- review site files and accountability logs
- ensure reporting of visit occurs in a timely manner and according to company
SOPs


Pharmacovigilance


* Report adverse events in compliance with regulatory requirements and company SOPs


Site Closure


* Ensure all data queries are resolved

* Ensure all essential documents are complete and filed appropriately

* Ensue accountability and reconciliation of study materials and investigational medicinal product


COMPETENCIES (KNOWLEDGE, SKILLS AND ATTRIBUTES)


* Establish and maintain relationships with internal/external contacts

* Prepare high quality documents for submission to Ethics Committees and Regulatory Authorities

* Track and plan regulatory activities to meet agreed timelines

* Maintain a current awareness of ethical and regulatory requirements

* Effective verbal and written communication in individual and group settings

* Ability to source information, research skills

* Ability to analyse and interpret data

* Excellent attention to detail

* Ability to plan, organise and follow up

* Effective time management of multiple tasks

* Negotiation skills

* Presentation skills

* Computer literacy


QUALIFICATIONS / EXPERIENCE

Required Qualifications / Experience:


* Graduate qualifications in Biological Sciences, Nursing, Pharmacy or related discipline

* At least 6 months experience as a CRA
Excellent working knowledge of ICH GCP guidelines

* Post-graduate qualifications desirable


Desirable Experience / Knowledge:


* Management of clinical trials/projects in Europe

aufklappen zuklappen Zusammenfassung
Stellenantritt
Ab sofort
Arbeitsort
Zurich
Kanton
Zürich
Arbeitsland
Schweiz
Anstellungsposition
Abteilungs- / Bereichsleitung
Anstellungsverhältnis
Festanstellung / Unbefristet
Arbeitspensum
Vollzeitstelle
Kategorie
Chemie / Pharma / Biotechnologie
Unterkategorie
Diverse
Inserate-ID
4978252
Firmenportrait


Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing its leading drug candidate afamelanotide (CUV1647).

Currently in Phase II and Phase III clinical trials, afamelanotide is being developed as a preventative photoprotective agent for five clinical applications.
Clinical Research Associate
Stellenbeschreibung

KEY RESULT AREAS

Study Feasibility Assessments


* Liaise with internal and external experts regarding proposed protocol scope, budget and timelines

* Identification, assessment and selection of appropriate investigators/sites and other service providers according to project requirements and company SOPs


Study Set-up


* Ensure site feasibility and preparation and execution of study initiation and associated meetings


Investigational Medicinal Product & Study Supplies


* Ensure all study materials including investigational medicinal products are procured appropriately and available on site when required

* Ensure all labeling requirements are met

* Assist in securing import documentation if necessary

* Arrange adequate storage and dispatch of investigational medicinal product and study materials to the investigational site


Document Management


* Collect and compile Essential Documents (according to ICH GCP guidelines and company SOPs)


Ethics Committee Documentation


* Prepare required HREC/IEC applications in a timely manner


Study Site Staff


* Train study staff in all study related processes / procedures

* Coordinate meetings with investigator as study site staff


Monitoring


* Monitoring the progress of clinical trials through regular visits and correspondence to ensure satisfactory conduct of trials including:
- monitor recruitment and consenting procedures
- adherence to the study protocol
- completion of CRFs and review of source data
- collection of data as specified in project plans
- review site files and accountability logs
- ensure reporting of visit occurs in a timely manner and according to company
SOPs


Pharmacovigilance


* Report adverse events in compliance with regulatory requirements and company SOPs


Site Closure


* Ensure all data queries are resolved

* Ensure all essential documents are complete and filed appropriately

* Ensue accountability and reconciliation of study materials and investigational medicinal product


COMPETENCIES (KNOWLEDGE, SKILLS AND ATTRIBUTES)


* Establish and maintain relationships with internal/external contacts

* Prepare high quality documents for submission to Ethics Committees and Regulatory Authorities

* Track and plan regulatory activities to meet agreed timelines

* Maintain a current awareness of ethical and regulatory requirements

* Effective verbal and written communication in individual and group settings

* Ability to source information, research skills

* Ability to analyse and interpret data

* Excellent attention to detail

* Ability to plan, organise and follow up

* Effective time management of multiple tasks

* Negotiation skills

* Presentation skills

* Computer literacy


QUALIFICATIONS / EXPERIENCE

Required Qualifications / Experience:


* Graduate qualifications in Biological Sciences, Nursing, Pharmacy or related discipline

* At least 6 months experience as a CRA
Excellent working knowledge of ICH GCP guidelines

* Post-graduate qualifications desirable


Desirable Experience / Knowledge:


* Management of clinical trials/projects in Europe

Clinuvel AG
Hauserstrasse 14
8032 Zurich
Referenz-Nr. CRA1712
Kontakt:
Frau Kate Egle

Telefon / Fax
Geschäft +41 44 253 75 0

http://www.nzzexecutive.ch/nzzexecutive/se...z0XFWHYrO/8A1fq
  Forum: By Share Code

arjan1972
Posted on: Dec 23 2008, 06:32 AM


Group: Member
Posts: 135


Here the 'web translation' of the German article (Source: Sunday Market/ sunday-market.de/) I am not am member so i can't give you the direct link.

Just 3 years it is, that with Clinuvel Pharmaceuticals the new management under the direction of CEO Philippe Wolgen the controls with him
to Australian pharmaceutical companies has taken over. After the old board of directors
with his strategy the enterprise nearly to the wall has gone, the new CEO prescribed a radical turn in the strategical adjustment. From now on for the chairman of the board only one purpose, the licensing from countedAfamelanotide (formerly CUV1647) by the FDA as a drug against 5 different, by ultraviolet rays caused, skin illnesses. Among experts the prevention and therapy of the cancer of the skin worldwide located in increase counts to the topical challenges of the today's medicine. If Clinuvel the successful market launch succeeds, Afamelanotide owns with it absolute Blockbusterpotential.
Besides, Afamelanotide stimulates the human body to the production of Eumelanin, a so-called Brownish black pigment that forms by an improved absorption of the ultraviolet rays, as can be proved a natural protection against the load of the solar effect. Besides, the active substance Afamelanotide is bet to the patients in form of a 4 mm implant under the skin where it resolves independently within less days and delivers the active substance thus in the right dosage to the body. Then a treatment should offer up to 60-day complete light protection or solar protection. Besides, above all light membranous patients show especially good test results. A true blessing for people like our former ridge Lady Hannelore Kohl who was condemned on grounds of an over-reaction of the skin against light, to a life in darkness. Now the interest of patients is accordingly big already. According to independent studies only the market volume should amount in the USA to more than 500 million dollars per year. If one estimates for the rest of the world once more a similar level, Clinuvel a billion market presents itself! Topically more than 450 patients with overriding success with Afamelanotide are treated in the clinical studies. 42 international universities look after the clinical phases and confirm the effectiveness. Clinuvel found out the first recognition by the American FDA already at the middle of the year with the preservation of the Orphan drug Designation (ODD), after already at the beginning of the year given the EMEA as well as Swiss licensing authority Clinuvel to the popular status. The ODD fights above all in diminished fees for the marketing Authorization Application (MAA) and a quickened licensing procedure down. Besides, the suitable enterprise receives a 10-year-old market exclusivity in Europe (7 years in the USA).

As to us head of the company Philippe Wolgen confirms in the background conversation, the licensing should be applied before Christmas by the FDA. From now on the US authority has 30 days for the investigation. We expect a final decision therefore at the end of January / beginning of February, 2009. Both most important short-term
Milestones for Clinuvel are therefore the IND-Filing with the FDA which we still expect before Christmas and the phase III Interresults for EPP. The development of the stock course does not shine to our opinion after the significant progress of Clinuvel during the last months again. Particularly as the pharmaceutical branch all together with weak research-pipelines and running out ones
To patents has to fight and Clinuvel therefore sooner or later on that
Shopping list of the Big player of the branch will land. If the enterprise has
Success, we go out in the medium term from a takeover.
Afamelanotide is topical
the worldwide only preventive drug for UV conditioned skin illnesses in
to a development stage advanced so far. The topical assessment level opens a favorable entrance level for investors conscious of risk. If the licensing succeeds by the FDA Clinuvel on a Blockbuster-drug for which a billion market presents itself sits. We see the Down-Size risk by the still respectable Cash upholsterer of just 30 million dollars restricted. 70% of the stock market value are covered by the cash reserve. With a Burn rate of less than 900,000 dollars per month istClinuvel for the clinical phases of 5 indications, besides, fully durchfinanziert. We advise the paper to shop with courses about 10 cents. We advise stop loss
To put 25% under entrance. The coming weeks are for the Australians of high meaning. This only could help the stock already to a new swing. Order, nevertheless, strictly limited. Topically you get the paper for a good price as never, however, the turnovers are also rather low.
  Forum: By Share Code

arjan1972
Posted on: Dec 23 2008, 06:10 AM


Group: Member
Posts: 135

interesting to see that some Trading threads in Germany re-discovered clinuvel. May have something to do with following information i found today in an article from the German financial Magazine ‘ Sunday Market’ on one of these sites
(http://www.cluboftraders.de/showthread.php?p=308581). In this article is reported that head of the company Philippe Wolgen confirmed to them in a background conversation, that the IND will be applied before Christmas. (the next 2 days..)

Here the original piece:


Knapp 3 Jahre ist es her, dass bei Clinuvel Pharmaceuticals das neue Management unter Leitung von CEO Philippe Wolgen das Steuer bei dem
australischen Pharmaunternehmen übernommen hat. Nachdem der alte Vorstand
mit seiner Strategie das Unternehmen beinahe an die Wand gefahren hat, verordnete der neue CEO eine radikale Wende in der strategischen Ausrichtung.
Für den Vorstandsvorsitzenden zählte von nun an nur ein Ziel, die Zulassung von
Afamelanotide (ehemals CUV1647) durch die FDA als Medikament gegen 5 verschiedene, durch UV-Strahlung hervorgerufene, Hautkrankheiten. Unter Experten zählt die Prävention und Therapie des weltweit in Zunahme befindlichen Hautkrebses zu den aktuellen Herausforderungen der heutigen Medizin. Gelingt Clinuvel die erfolgreiche Markteinführung, besitzt Afamelanotide damit absolutes Blockbusterpotential. Afamelanotide regt dabei den menschlichen Körper zur Produktion von Eumelanin, einem so genannten Schwarz-Braun Pigment an, dass durch eine verbesserte Absorption der UV-Strahlung, nachweislich einen natürlichen Schutz gegen die Belastung der Sonneneinwirkung bildet. Der Wirkstoff Afamelanotide wird dabei den Patienten in Form eines 4mm großen Implantats unter die Haut gesetzt, wo es sich selbständig innerhalb weniger Tage auflöst und den Wirkstoff so in der richtigen Dosierung an den Körper abgibt. Eine Behandlung soll dann bis zu 60 Tage kompletten Licht- bzw. Sonnenschutz bieten. Dabei zeigen vor allem hellhäutige Patienten besonders gute Testergebnisse. Ein wahrer Segen für Menschen wie unsere ehemalige First Lady Hannelore Kohl, die auf Grund einer Überreaktion der Haut gegen Licht, zu einem Leben in Dunkelheit verdammt war. Entsprechend groß ist bereits jetzt das Interesse von Patienten. Laut unabhängigen Studien soll sich alleine das Marktvolumen in den USA auf über 500 Millionen Dollar pro Jahr belaufen. Schätzt man für den Rest der Welt noch mal ein ähnliches Niveau, eröffnet sich Clinuvel ein Milliarden-Markt! Aktuell werden in den klinischen Studien über 450 Patienten mit überragendem Erfolg mit Afamelanotide behandelt. 42 internationale Universitäten betreuen die klinischen Phasen und bestätigen die Wirksamkeit. Erste Anerkennung durch die amerikanische FDA erfuhr Clinuvel bereits Mitte des Jahres mit dem Erhalt der Orphan Drug Designation (ODD), nachdem bereits Anfang des Jahres sowohl die EMEA als auch die Schweizerische Zulassungsbehörde Clinuvel den begehrten Status erteilte. Die ODD schlägt sich vor allem in reduzierten Gebühren für die Marketing Authorization Application
(MAA) und einem beschleunigten Zulassungsverfahren nieder. Zudem erhält das entsprechende Unternehmen eine 10-jährige Marktexklusivität in Europa (7 Jahre in USA).

Wie uns Firmenchef Philippe Wolgen im Hintergrundgespräch bestätigt, soll vor Weihnachten die Zulassung durch die FDA beantragt werden. Fortan hat die US-Behörde 30 Tage zur Begutachtung. Eine finale Entscheidung erwarten wir somit Ende Januar / Anfang Februar 2009. Die beiden wichtigsten kurzfristigen
Milestones für Clinuvel sind somit das IND-Filing bei der FDA, das wir noch vor Weihnachten erwarten und die Phase III Zwischenergebnisse für EPP. Die Entwicklung des Aktienkurses spiegelt unserer Meinung nach die bedeutenden Fortschritte von Clinuvel in den letzten Monaten nicht wieder. Zumal die Pharmabranche insgesamt mit schwachen Forschungs-Pipelines und auslaufenden
Patenten zu kämpfen hat und Clinuvel somit über kurz oder lang auf der
Einkaufsliste der Big Player der Branche landen wird. Hat das Unternehmen
Erfolg, gehen wir mittelfristig von einer Ãœbernahme aus. Afamelanotide ist aktuell
das weltweit einzige präventive Medikament für UV-bedingte Hautkrankheiten in
einem so weit fortgeschrittenen Entwicklungsstadium. Das aktuelle Bewertungsniveau eröffnet risikobewussten Anlegern ein günstiges Einstiegsniveau. Gelingt die Zulassung durch die FDA sitzt Clinuvel auf einem Blockbuster- Medikament, dem sich ein Milliardenmarkt eröffnet. Das Down-Size Risiko sehen wir durch das nach wie vor solide Cash-Polster von knapp 30
Millionen Dollar begrenzt. 70% des Börsenwertes werden durch den Barbestand abgedeckt. Mit einer Burn-Rate von weniger als 900.000 Dollar pro Monat ist
Clinuvel für die klinischen Phasen der 5 Indikationen zudem voll durchfinanziert. Wir raten das Papier bei Kursen um 10 Cent zu kaufen. Stoppkurse raten wir
25% unter Einstieg zu setzen. Die kommenden Wochen sind für die Australier von hoher Bedeutung. Das allein könnte der Aktie schon zu einem neuen Schwung verhelfen. Ordern Sie jedoch streng limitiert. Aktuell bekommen Sie das Papier günstig wie nie, jedoch sind auch die Umsätze recht gering.[I]
  Forum: By Share Code

arjan1972
Posted on: Dec 18 2008, 10:22 PM


Group: Member
Posts: 135

QUOTE (ad0304s @ Thursday 18/12/08 02:08pm)

I'd go for the boomerang effekt. The US Economy is failing, the Fed and the government are out of Ideas. The US States and Firms are living with huge debts and are not able to pay.

More people are recognizing this every day and hurry to get out of the US Dollar. This will crash the US Dollar and the United States.
  Forum: By Share Code

arjan1972
Posted on: Dec 18 2008, 09:27 PM


Group: Member
Posts: 135

In reply to: ad0304s on Thursday 18/12/08 08:35am

the Dollar is recently falling like a stone , and it may fall under the table right into hyperinflation. Therefore i am glad that Clinuvel is a company backed by AUS Dollar.
Of course i am also disappointed in the SP of CUV, but we all knew that this could happen. CUV still is a high speculative Stock, and the demand for this kind of stock ist very low right now. So if you are going to sell, you are not going to get a lot of money for it.

It’s also a shame that Clinuvel is doing a lousy job in informing his investors and leaving them in the dark.

On the other site, i still don't see any real reasons to believe that something has gone wrong big time at the medical trials or in the financial management of the company.
For guys with cash this is the chance of a lifetime to get in for unreal prices.

I bought CUV as a long term investment and i still believe in the technologie. Yes, It is a rough ride but i will keep my CUV Stock to the End. And in my opinion it will be succesfull.
  Forum: By Share Code

arjan1972
Posted on: Nov 27 2008, 12:26 AM


Group: Member
Posts: 135

i own 100.000 CUV shares
  Forum: By Share Code

arjan1972
Posted on: Oct 9 2008, 04:09 AM


Group: Member
Posts: 135

unbelievable panic selling! today some guys sold their CUV shares at 0,08 cents. How low can you go? I managed to get myself another 8000 shares at 10,5 cents! I had to do it! cant believe that it's getting lower then that.. or do i? blink.gif
  Forum: By Share Code

arjan1972
Posted on: Sep 30 2008, 07:49 AM


Group: Member
Posts: 135

watch Ron Paul on the Bailout Failure 9/29/09

http://www.youtube.com/watch?v=WJ7dQ955HJ4
  Forum: By Share Code

arjan1972
Posted on: Sep 30 2008, 04:15 AM


Group: Member
Posts: 135

In reply to: Rosewood on Monday 29/09/08 07:47pm

take the pain..

my humble opinion is that the bailout bill will only slowdown the economic crash. But its coming anyway. Let's take the pain of two broken legs and take the chance to build up a healthy system.




  Forum: By Share Code

arjan1972
Posted on: Sep 22 2008, 01:31 AM


Group: Member
Posts: 135

In reply to: Rosewood on Friday 19/09/08 02:40am

last Friday CUV had a unbelievable 43% up at the German DAX. I am very curious what happens at the ASX today!


Attached image(s)
Attached Image

 
  Forum: By Share Code

arjan1972
Posted on: Sep 15 2008, 07:07 PM


Group: Member
Posts: 135

QUOTE (controvers @ Sunday 14/09/08 07:49pm)

Dear Contro,

in one thing you're right: you can't compare this crisis with the crisis of the twenties.
It could be worse this time.. the collapse of the financial system is happening - right now - and right in front of you. Wake up! Read some papers, do you're homework!

http://www.dailymail.co.uk/news/worldnews/...n-Brothers.html

How bad it's going to be? Nobody knows i guess. Maybe the smart boys and Girls of the international Financial Institutes can solve it.. I certainly hope so.
I'll do it like Rosewood.. no panic nor give away my shares for a pittance. Try to relax and wait till the storm is over! wink.gif
Good luck!
  Forum: By Share Code

arjan1972
Posted on: Sep 14 2008, 11:37 PM


Group: Member
Posts: 135

QUOTE (uhohinc @ Saturday 13/09/08 07:49am)

Fannie Mae and Freddie Mac being nationalised by the us government is indead a scary deal and could drive the US in bankruptcy..It's obvious that the credit crisis hasn't cooled down. Nor have the huge financial institutions, which are going down in flames right now!

I sure hope that Clinuvels Management Team does the right thing with the Dollars they still have. It might be difficult to get a loan in the next ten years.
  Forum: By Share Code

arjan1972
Posted on: Sep 11 2008, 10:20 PM


Group: Member
Posts: 135

weirdsmiley.gif


Attached image(s)
Attached Image

 
  Forum: By Share Code

arjan1972
Posted on: Sep 10 2008, 08:09 PM


Group: Member
Posts: 135

Dear all,

still going down, CUV currently melting down another 3% to 0.15,7 Euro

I hope I am wrong but I think this time CUV is going down big time.

Buying opportunity? maybe.. but we all know the old saying ' never catch a falling knife '
Attached image(s)
Attached Image

 
  Forum: By Share Code

arjan1972
Posted on: Sep 4 2008, 09:07 PM


Group: Member
Posts: 135

QUOTE (ognid @ Thursday 04/09/08 11:19am)

20 cents is the range?

I sure hope that CUV will get that value again. We're going down to 17 Cents here in Europe.. Why is that? I really do not understand this negative growth and I am getting nervous about it! Seriously, I see small Films were Swiss doctors are talking hilarious positive about CUV, CUV is in Phase 3, Orphan status, good Chances to go to market in the next two years, thats all good news! and that in combination with a terrible SP (and still going down!) I don't get it!

I keep this stock since the first Days it came to Europe, and experienced all the good and bad times since.. Every time it went down was the time for me to buy more CUV. I was relaxed and convinced that this Produkt will be a major Blockbuster. But this time its different. In the last years the floor was reached at approx. 0,19 Cents on the Dax. We're now on 17 Cents.. and still sinking. Wtf is going on? Ist there something we don't know?

I am holding on.. but I am getting more and more impatienced..

Maybe i should start doing yoga
  Forum: By Share Code

arjan1972
Posted on: Sep 1 2008, 08:57 PM


Group: Member
Posts: 135

We need some good news. The SP on the DAX is the lowest since introduction.. weirdsmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Aug 23 2008, 09:25 PM


Group: Member
Posts: 135

In reply to: uhohinc on Saturday 23/08/08 10:35am

Hi Mike,

interesting idea. I like it. Of course there is the question whether this plan is realistic icon14.gif


Arjan
  Forum: By Share Code

arjan1972
Posted on: Aug 20 2008, 05:35 AM


Group: Member
Posts: 135

In reply to: rabbitrun on Tuesday 19/08/08 02:26pm

Dear Contro,

i still think the recent SP has not much to do with CUV. Dax down almost 3% today..it's about a bear market..



  Forum: By Share Code

arjan1972
Posted on: Jun 17 2008, 11:59 PM


Group: Member
Posts: 135

CUV just jumped 22% in Germany.. News? or a mistake? icon14.gif
  Forum: By Share Code

arjan1972
Posted on: Jun 12 2008, 04:12 PM


Group: Member
Posts: 135

In reply to: Gordon Geko on Thursday 12/06/08 07:25am

I can only confirm Gordons Story. It functions. The technology is undisputed Great. cool.gif
  Forum: By Share Code

arjan1972
Posted on: Jun 8 2008, 11:13 PM


Group: Member
Posts: 135

In reply to: campbellkaryn on Sunday 08/06/08 12:36pm

A contribution can also be a critical one and doesn't has to be some halleluja story of a blindfolded believer. If you don't want to read it scroll on...it's a free world. ph34r.gif
  Forum: By Share Code

arjan1972
Posted on: Jun 5 2008, 11:01 AM


Group: Member
Posts: 135

QUOTE (KRD @ Wednesday 04/06/08 04:19pm)

The irritation is gettin' SKINdeep with this management....... grrr.gif
  Forum: By Share Code

arjan1972
Posted on: Mar 20 2008, 08:56 PM


Group: Member
Posts: 135

http://www.clinuvel.com//resources/pdf/ana...3-07ABNAMRO.pdf


300% yet to come......from now.....
  Forum: By Share Code

arjan1972
Posted on: Mar 14 2008, 09:30 PM


Group: Member
Posts: 135

http://www.clinuvel.com//resources/pdf/ana...3-07ABNAMRO.pdf
  Forum: By Share Code

arjan1972
Posted on: Feb 12 2008, 09:18 PM


Group: Member
Posts: 135

In reply to: Klomp on Tuesday 12/02/08 12:39pm

I completely agree with you klomp..... it is and will stay a bet for the coming few years.

If you expect a fast return on investment or an even faster 100% loss, then go to a casino betting on the roulette table, red or black.

If you can´t handle this stress then put your savings on a savingaccount against 3 to 4 % pa.

The rest of us believers keep up the faith and hope for the best.

  Forum: By Share Code

arjan1972
Posted on: Feb 12 2008, 06:09 PM


Group: Member
Posts: 135

4.7 mln. shares ....... wacko.gif somebody has the faith in this company.....

  Forum: By Share Code

arjan1972
Posted on: Feb 6 2008, 09:06 PM


Group: Member
Posts: 135

http://www.clinuvel.com/resources/pdf/anal...NAMROUpdate.pdf
  Forum: By Share Code

arjan1972
Posted on: Jan 26 2008, 10:21 AM


Group: Member
Posts: 135

In reply to: controvers on Friday 25/01/08 07:00pm

I just wanted to mention the following as a quote on all the negative posts lately :

Besides we, the shareholders, small or large investors, there are a few people who are even more interested in a big succes for this company. These people are Mr. Wolgen and his Staff.

With a lot of options and the rest of his career depending on the succes of CUV he is the one who is most interested in bringing this to the market. Ok..... al lot of mistakes have been made..... but i truly believe in him doing his weirdsmiley.gif best for clinuvel.
  Forum: By Share Code

arjan1972
Posted on: Nov 29 2007, 06:53 PM


Group: Member
Posts: 135

Mr. O. Homm in private? rolleyes.gif
  Forum: By Share Code

arjan1972
Posted on: Nov 9 2007, 03:00 PM


Group: Member
Posts: 135

Patent Announcement Now or ?

November 2007 should have the moment as far as i remember.....or is this also going to be sometime in 2008?

Who has the right information.......

  Forum: By Share Code

arjan1972
Posted on: Nov 6 2007, 06:11 PM


Group: Member
Posts: 135

http://quotes.nasdaq.com/quote.dll?page=ch...TN&selected=PTN
  Forum: By Share Code

arjan1972
Posted on: Nov 6 2007, 06:08 PM


Group: Member
Posts: 135

http://quotes.nasdaq.com/quote.dll?page=ch...TN&selected=PTN

Once upon a time there was a fund called Palatin, it reached the level of $10,00 in the good days. Now it´s value is $0,37. weirdsmiley.gif

Onde upon a time there was a fund called Clinuvel, in Germany it started at $0,50. The good days are still to come. biggrin.gif

  Forum: By Share Code

arjan1972
Posted on: Oct 5 2007, 05:59 PM


Group: Member
Posts: 135

In reply to: artwolf on Friday 05/10/07 08:48am

Everybody agrees with that statement but still they´re sitting on millions of cash.... sad.gif
  Forum: By Share Code

arjan1972
Posted on: Sep 28 2007, 01:09 PM


Group: Member
Posts: 135

There´s no bottom.....ok....just one......ZERO! sadsmiley02.gif thumbdown.gif
  Forum: By Share Code

arjan1972
Posted on: Jul 9 2007, 03:41 AM


Group: Member
Posts: 135

In reply to: traveler on Sunday 08/07/07 07:32pm

why not.. might be fun!
  Forum: By Share Code

arjan1972
Posted on: Jun 26 2007, 04:09 PM


Group: Member
Posts: 135

this stock is driving me crazy.. Can someboby explain the current fall? i don't see any reason. mad.gif
  Forum: By Share Code

arjan1972
Posted on: May 21 2007, 07:10 PM


Group: Member
Posts: 135

In reply to: imprezawrx on Monday 21/05/07 08:30am

why? did they call you?
  Forum: By Share Code

arjan1972
Posted on: May 19 2007, 01:58 AM


Group: Member
Posts: 135

In reply to: traveler on Friday 18/05/07 07:17am

i guess most CUV Investors already have a prior history of taking psychotropic medications weirdsmiley.gif
  Forum: By Share Code

arjan1972
Posted on: May 4 2007, 04:14 AM


Group: Member
Posts: 135

In reply to: KRD on Thursday 03/05/07 08:06pm

Your word in god's ear.... cool.gif
  Forum: By Share Code

arjan1972
Posted on: Apr 27 2007, 01:25 AM


Group: Member
Posts: 135

Despite the negative news of short-term priceloss this is positive news because of :

-Enough cash until the end of fase III
-A fifth indication
-What do you think the shareprice will do in the nearby future if a company buys almost 25 mil. shares now with a price of AU$1,07???

The only way is up...

icon13.gif
  Forum: By Share Code

arjan1972
Posted on: Apr 26 2007, 07:35 AM


Group: Member
Posts: 135


Mission Statement

Most importantly, Clinuvel focuses on:

1. Addressing UV related medical disorders;
2. Maximising shareholder returns;


Well....let´s see what tomorrow brings.....
  Forum: By Share Code

arjan1972
Posted on: Apr 25 2007, 01:26 AM


Group: Member
Posts: 135

We´ll have to wait for another 2 days max. to know how many AU$/€/US$ they stole from us.....or what kind of late easterpresent they will show us.

So put out your PC´s/laptops and take a deep rest.

stun.gif
  Forum: By Share Code

arjan1972
Posted on: Mar 26 2007, 12:56 PM


Group: Member
Posts: 135

AU$1,12....it goes on...and on....and.... cool.gif
  Forum: By Share Code

arjan1972
Posted on: Mar 23 2007, 06:38 AM


Group: Member
Posts: 135

In Europe (Frankfurt-Germany) we have 2 eurocents to go until the all time high of €0,68.

Will it be this month or the next one to break this record? Every month we need positive news to atract more and more investers and to push the stockprice.

  Forum: By Share Code

arjan1972
Posted on: Mar 6 2007, 08:20 PM


Group: Member
Posts: 135

Benjammin...you´re absolutely right.....(funny statement with Absolute Capital as main shareholder isn´t it?).

The only thing i wish is that those small sellers (are they small sellers?) who think they have the skills for perfect timing and think they are smarter that the market will sell now for AU§ 0,90 or less and have to stepp in again for AU$ 1,00 or more. They can only try that kind of tricks a few times before running out of cash.

  Forum: By Share Code

arjan1972
Posted on: Mar 6 2007, 09:17 AM


Group: Member
Posts: 135

Bid AU$ 1,10 Offer 0,85

Let´s agree all together not to sell for less than AU$ 5,00 ....

Credo for 2007.... Only an idiot sells now.

  Forum: By Share Code

arjan1972
Posted on: Feb 15 2007, 11:52 PM


Group: Member
Posts: 135

In reply to: woteva on Thursday 15/02/07 02:55pm

Hello Woteva,

It is not the question of acception...... we don´t accept it....but the main problem is....we can´t change it.... not even on a global level.
  Forum: By Share Code

arjan1972
Posted on: Feb 15 2007, 09:53 PM


Group: Member
Posts: 135

Not funny te read al those endless positive posts changing to depressing future scenarios in such a short time. Wake up everybody....we live in the MeMyselfandIMillenium.....so make your strategy to cash the best you can. icon13.gif

  Forum: By Share Code

arjan1972
Posted on: Jan 29 2007, 08:50 AM


Group: Member
Posts: 135

All stocks are going down....but not for CUV.....will it be a stairway to the sun cool.gif ..... laughingsmiley.gif bidprice now.... AUS$0,90.... sounds good, 10% every month! cool.gif
  Forum: By Share Code

arjan1972
Posted on: Jan 23 2007, 07:17 AM


Group: Member
Posts: 135

In reply to: KRD on Monday 22/01/07 11:00pm

Thank You for the info.... icon13.gif
  Forum: By Share Code

arjan1972
Posted on: Jan 22 2007, 09:33 PM


Group: Member
Posts: 135

January, February, March, April or May 2007.... it really doesn´t matter.... i strongly believe we will see AUS$ 1,50 and in Europe € 1,00 before the end of this year. Just be patient. hypocrite.gif

Concerning the anouncement of today, does anybody know how to buy these options. Are they available in Australia only or also in the US and Germany? icon14.gif ohmy.gif





  Forum: By Share Code

arjan1972
Posted on: Jan 17 2007, 12:42 AM


Group: Member
Posts: 135

In reply to: SpookyOz on Tuesday 16/01/07 03:35pm

were in the fiftys again in Frankfurt! cool.gif
  Forum: By Share Code

arjan1972
Posted on: Jan 4 2007, 07:32 AM


Group: Member
Posts: 135

In reply to: paufin on Wednesday 03/01/07 10:03pm
  Forum: By Share Code

arjan1972
Posted on: Jan 3 2007, 09:23 PM


Group: Member
Posts: 135

cant believe it, 50 cents in Frankfurt.. and still going! There must be some news.. ph34r.gif
  Forum: By Share Code

arjan1972
Posted on: Dec 28 2006, 08:38 PM


Group: Member
Posts: 135

In reply to: imprezawrx on Thursday 28/12/06 08:12am

we did hit the 0,45 cents this morning in Frankfurt.. back on 0,41 cents now but the feeling is good..very good lmaosmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Dec 23 2006, 09:39 PM


Group: Member
Posts: 135

Prettige kerst en een gelukkig 2007!

Greetings from the Netherlands!
Arjan

smile.gif

  Forum: By Share Code

arjan1972
Posted on: Nov 19 2006, 05:58 AM


Group: Member
Posts: 135

http://healthnews.uc.edu/news/?/3688/ so we have some real competition for Clinuvel.. do we need to worry? weirdsmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Nov 8 2006, 04:46 AM


Group: Member
Posts: 135

In reply to: happy2 on Tuesday 07/11/06 02:43pm

icon14.gif highest SP since a long long time today in Germany... 0,32 Cents (almost 0,53 AUD)!
Attached image(s)
Attached Image

 
  Forum: By Share Code

arjan1972
Posted on: Oct 3 2006, 12:09 AM


Group: Member
Posts: 135

just read that Mr. Homm and his absolute Capital Group are now proud owner of 29.440.508 Clinuvel shares...thats a lot of power... sadsmiley02.gif

  Forum: By Share Code

arjan1972
Posted on: Sep 6 2006, 01:13 AM


Group: Member
Posts: 135

In reply to: paufin on Tuesday 05/09/06 04:59pm

www.dax.de you have to write Clinuvel at 'Kurssuche' and then you go..
  Forum: By Share Code

arjan1972
Posted on: Sep 6 2006, 12:48 AM


Group: Member
Posts: 135

WOW! CUV jumps at 27 cents in Europe! thats a plus of 17%! lmaosmiley.gif

  Forum: By Share Code

arjan1972
Posted on: Aug 2 2006, 10:12 PM


Group: Member
Posts: 135

and so we did.. sad.gif
  Forum: By Share Code

arjan1972
Posted on: Jul 8 2006, 06:06 PM


Group: Member
Posts: 135

In reply to: woteva on Saturday 08/07/06 04:51am

Great Post! Thanx for sharing from the european front! smile.gif
  Forum: By Share Code

arjan1972
Posted on: Jun 26 2006, 03:57 PM


Group: Member
Posts: 135

In reply to: traveler on Monday 26/06/06 04:30am

ok, you made made me curious now.. what company are u talking about:icon14:
  Forum: By Share Code

arjan1972
Posted on: May 4 2006, 06:10 AM


Group: Member
Posts: 135

In reply to: TongPo on Wednesday 03/05/06 11:14am

Dear TongPo..

MTI= Clinuvel / MTII=Palatin graduated.gif

i guess you meant MTI...

  Forum: By Share Code

arjan1972
Posted on: Apr 30 2006, 05:45 PM


Group: Member
Posts: 135

In reply to: Go4it on Saturday 29/04/06 11:01pm

Got the same problem here, grrr.gif lots of Spam with trading alerts.. wtf! Somebody knows what to do? hate the fact that somebody got my e.mail adress from this site and is using it to spam me! Dear Sharescene Administrator: what are you doing against it? i never wanted to 'share' my e.mail with the whole 'scene'
  Forum: By Share Code

arjan1972
Posted on: Mar 25 2006, 05:04 AM


Group: Member
Posts: 135

SP plus 13,9% today icon13.gif Why? icon14.gif
  Forum: By Share Code

arjan1972
Posted on: Mar 12 2006, 05:28 AM


Group: Member
Posts: 135

In reply to: DomEm on Saturday 11/03/06 08:50pm

he sure is a man of controversy.. anything is possible.. positive & negative

I know the melanotan.org site, but not under this name. I guess you mean 'Rotterdam'.
we share the same name.

  Forum: By Share Code

arjan1972
Posted on: Mar 12 2006, 04:11 AM


Group: Member
Posts: 135


The CIO of Absolute Capital, Florian Homm, is not somebody with a lot of patience. Its all about the results now! Thats the exciting thing right now.. there is not only a stopwatch in their office with a time somewere in 2009.. but there is also one in the Spanish office of Mr. Homm. This Mr. Homm, wellknown for his actions on the German (stock)markets, will observe CUV precisely and if CUV is reaching the Milestones in time they wil get the reward for that. If not.. in that case - i guess - Absolute Capital will be quicker out of CUV as Millen in his golfshoes. wink.gif

I hope this pressure will work out positive on CUV! and to be honest, i think it will. king.gif

Good Luck to all! &
Groeten uit Nederland!

A.


  Forum: By Share Code

arjan1972
Posted on: Jan 15 2006, 07:30 PM


Group: Member
Posts: 135

In reply to: noddy1958 on Saturday 14/01/06 11:58pm

Lets get real here, most stockholders, including the major ones are speculating on the cosmetic and sunburnprotecting effects. All the other effects are nice, preventing PMLE for example, but the money will be made in the cosmetic sector.
  Forum: By Share Code

arjan1972
Posted on: Jan 15 2006, 05:59 AM


Group: Member
Posts: 135

In reply to: hayboys on Saturday 14/01/06 07:33pm

Rotterdam is right, if you try this product then you know for sure.. it's the real deal! It not only makes skintype 1 turn brown but it also keeps you from burning for sure. I can tell also, i tried it like Rotterdam. And the results made me buy the stock, not the illusion.

Of course its still risky, but you want believe how many people are screaming for a product like this..and the beautifull thing about Epitan is that they allready have it..we just have to wait and hope that the medical Trials go out positive.
  Forum: By Share Code

arjan1972
Posted on: Dec 29 2005, 07:35 PM


Group: Member
Posts: 135

In reply to: rotterdam on Thursday 29/12/05 11:04am

Heeee!

Mr. Rotterdam! welkom aan boord!

  Forum: By Share Code

arjan1972
Posted on: Dec 23 2005, 06:38 PM


Group: Member
Posts: 135

In reply to: woteva on Friday 23/12/05 06:05am

Just to be sure.. gold stocks=EPT? wink.gif
  Forum: By Share Code

arjan1972
Posted on: Dec 21 2005, 01:51 AM


Group: Member
Posts: 135

In reply to: zipper on Tuesday 20/12/05 07:16am

Hmmm.. and again we all can buy this stock for a real good price!! biggrin.gif
  Forum: By Share Code

arjan1972
Posted on: Dec 9 2005, 11:13 PM


Group: Member
Posts: 135

why do i have that feeling that this maybe the last chance to buy ept for this low price? I just have to buy more... i must be addicted!!! Help! lmaosmiley.gif
  Forum: By Share Code

arjan1972
Posted on: Nov 12 2005, 05:12 AM


Group: Member
Posts: 135

blink.gif Ept at the lowest point this year 0,20 Eurocents... WTF is going on?
  Forum: By Share Code

arjan1972
Posted on: Nov 7 2005, 08:13 AM


Group: Member
Posts: 135

In reply to: roadrunner on Monday 07/11/05 06:27am

Good to know that, i just bought Ept at the Dax-Germany. I strongly believe in this product, it has a gigantic market potential. My only fear is that competitors come up with a better product.

Greetings from the Netherlands!
  Forum: By Share Code

arjan1972
Posted on: Nov 7 2005, 04:32 AM


Group: Member
Posts: 135

Just read something about MelanX, i never heard of it before but if it is real it could be a real threat for Epitan. I found it on melanotan.org.
quote: Jay1964:
The technology was invented by a professor at the University of Oklahoma in 1996, a highly respected authority on skin pigmentation. A start-up company called MelanX was created by the University to develop and commercalize the product. Unfortunately they ran out of money and the whole process stopped for a few years.

Back in 2001 he was recruited by a new company called Cutanix to help them get some of their products for rosecea onto the market. Shortly after, Cutanix licensed his pigmentation technology in the hopes of brining it to the market.

Well, that never happened either (frustrating as hell!). They made lots of promises and predictions for release but they never came through. Turns out, the inventor of the technology was very frustrated with Cutanix as they put his technology on the bottom of their priority list (compared to their other products). He ended up leaving Cutanix in late 2004 and took his technology with him. That's why you're not getting any response from Cutanix.

One of the last emails I received from him, he said that he has formed his own company and is now "aggressively pursuing the development of the tanning product, something I was unable to do at Cutanix".

As far as clinical trials taking years for his product, that won't be the case. It's his intention to release the technology on the market as a cosmetic by limiting the label claims on the product. It's not uncommon.
  Forum: By Share Code


Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING